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SUMMARY 
 
Coronary artery disease (CAD) is one of the leading causes of mortality in 
developed countries. It most often results from atherosclerosis, a progressive condition 
characterized by the accumulation of lipids and fibrous elements in the large arteries. 
Many inflammatory proteins are elevated in this process and correlated with future 
coronary events. One of such inflammatory proteins is serum amyloid A (SAA). SAA is 
an acute phase protein whose level of expression increases markedly during bacterial 
infection, tissue damage, and inflammation. The potential beneficial roles of SAA include 
its involvement in reverse cholesterol transport and possibly extracellular lipid deposition 
at sites of inflammation and tissue repair. It is an attractive therapeutic target for the 
treatment of atherosclerosis. Peroxisome proliferator-activated receptor γ (PPARγ) plays 
a major regulatory role in adipogenesis and in the expression of genes involved in lipid 
metabolism. Activation of PPARγ leads to multiple changes in gene expression, some of 
which are believed to be atherogenic while others are antiatherogenic. In this study, we 
investigated the effects of SAA on PPARγ activation and its downstream target gene 
expression profiles in HepG2 cells. We demonstrated that SAA could activate PPARγ 
transcriptional activity. Preincubation of HepG2 cells with SAA enhanced the efflux of 
cholesterol to HDL and apoA-I. In addition, SAA increased the level of intracellular 15-
deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), which is a potent natural ligand for PPARγ.  
Our data suggested that SAA activated PPARγ through extracellular signal-regulated 
kinase 1/2 (ERK1/2) and NF-кB dependent COX-2 expression. Furthermore, SAA-
induced cholesterol efflux was suppressed when the ERK1/2 pathway or COX-2 was 
inhibited. Overall, our study has established, for the first time, a relationship between 
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SAA and PPARγ. Additionally, the data from our study has also provided new insights 
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1.1 CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS  
Coronary arteries deliver oxygen-rich blood to the myocardium. Coronary artery 
disease (CAD) is the end result of the accumulation of atheromatous plaques within the 
walls of the coronary arteries that supply the myocardium with oxygen and nutrients. It is 
sometimes also called coronary heart disease (CHD). CAD is the most common form of 
heart disease. It is one of the leading causes of mortality in developed countries [1]. It 
most often results from atherosclerosis, a progressive condition characterized by the 
accumulation of lipids and fibrous elements in the large arteries. 
 
1.2 ATHEROSCLEROSIS DEVELOPMENT 
Our views of the pathophysiology of atherosclerosis have evolved substantially 
over the past century. The link between lipids and atherosclerosis dominated our thinking 
based on strong experimental and clinical relationships between hypercholesterolaemia 
and atheroma [2]. More recently, a prominent role of inflammation was discovered for 
the development of atherosclerosis and its complications [3-5]. In fact, the lesions of 
atherosclerosis represent a series of highly specific cellular and molecular responses that 
can best be described, in aggregate, as an inflammatory disease [6]. 
 The earliest changes that precede the formation of lesions of atherosclerosis take 
place in the endothelium. These changes include increased endothelial permeability to 
lipoproteins and other plasma constituents, up-regulation of leukocyte adhesion 
molecules, up-regulation of endothelial adhesion molecules, and migration of leukocytes 
into the artery wall (Fig. 1a). Then the fatty streaks start to build up in the arteries. Fatty 
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streaks initially consist of lipid –laden monocytes and macrophages (foam cells) together 
with T lymphocytes. Later they are joined by various numbers of smooth-muscle cells 
(Fig. 1b). The steps involved in this process include smooth-muscle migration, T-cell 
activation, foam cell formation, and platelet adherence and aggregation. As fatty streaks 
progress to intermediate and advanced lesions, they tend to form a fibrous cap that walls 
off the lesion from the lumen (Fig. 1c). This represents a type of healing or fibrous 
response to the injury. The fibrous cap covers a mixture of leukocytes, lipid, and debris, 
which may form a necrotic core. Continuing influx and activation of macrophages could 
increase metalloproteinases and other proteolytic enzymes at the advanced lesion, which 
results in the thinning of the fibrous cap (Fig. 1d). Finally, rupture of the fibrous cap can 
rapidly lead to thrombosis and occlusion of the artery. It usually occurs at sites of 










    
(a) (b) 
    
                           (c)                                                        (d) 
 
Figure 1. Schematic representation of the atherosclerotic lesion development. 
(a) Endothelial dysfunction in atherosclerosis. (b) Fatty-streak formation in 
atherosclerosis. (c) Formation of an advanced, complicated lesion of atherosclerosis. (d) 
Unstable fibrous plaques in atherosclerosis (Adapted from Ref. [3]).  
 
1.3  INFLAMMATORY FACTORS IN ATHEROSCLEROSIS  
 In the past decades, an increasing number of inflammatory factors were revealed 
to play a role in atherosclerosis [7]. The effectors of the immune system are involved 
directly in all stages of atherogenesis [3]. Endothelial dysfunction takes place before the 
formation of lesions of atherosclerosis. The endothelial permeability is increased, which 
is mediated by nitric oxide (NO), prostacyclin, platelet-derived growth factor (PDGF), 
angiotension II, and endothelin. The leukocyte adhesion molecules are up-regulated, 
including L-selectin, integrins, and platelet-endothelial-cell adhesion molecule 1 
(PECAM-1). The endothelium-derived cellular adhesion molecules (CAMs) are also up-
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regulated, which include endothelial cell-derived selectin (E-selectin), intercellular 
adhesion molecule 1 (ICAM-1), and vascular-cell adhesion molecule 1 (VCAM-1). The 
leukocytes finally enter into the artery wall, which is mediated by oxidized low density 
lipoprotein (ox-LDL), monocyte chemotactic protein 1 (MCP-1), interleukin-8 (IL-8), 
PDGF, macrophage colony-stimulating factor (CSF), and osteopontin. Subsequently, 
fatty streaks begin to build up, which is mediated by PDGF, fibroblast growth factor 2 
(FGF-2), transforming growth factor β (TGF-β). T-cell activation is mediated by tumor 
necrosis factor α (TNFα), interleukin-1 (IL-1), interleukin-2 (IL-2), and granulocyte-
macrophage CSF. Foam cell formation is mediated by ox-LDL, macrophage CSF, TNFα, 
and IL-1. Platelet adherence and aggregation are stimulated by integrins, P-selectin, 
fibrin, thromboxane A2 (TXA2), and tissue factor (TF). As fatty streaks progress to 
advanced lesion, the principal factors associated with macrophage accumulation include 
macrophage CSF, monocyte chemotactic protein 1 (MCP-1), and ox-LDL. Thinning of 
the fibrous cap is apparently due to matrix metalloproteinsease (MMPs) and other 
proteolytic enzymes released from vaso-related cells at these sites. These enzymes can 
cause matrix degradation and plaque rupture, and eventually result in acute coronary 
events. 
 Histological studies have shown immune cells accumulating in the atherosclerotic 
lesions, including monocuclear phagocytes, lymphocytes and mast cells. Inflammatory 
proteins such as cytokines, chemokines, adhesion molecules, and acute phase proteins 
have been found to be highly expressed in atheroma as well. In addition, many 
inflammatory proteins have also been shown to be elevated in CAD [8]. The Women’s 
Health Study showed that 4 inflammatory markers, C-reactive  protein (CRP), serum 
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amyloid A (SAA), IL-6 and ICAM-1, were significant predictors of CAD risk [9, 10]. 
Among them, CRP and SAA were the strongest predictors of CAD risk. Interestingly, 
both CRP and SAA are major acute phase proteins which can be induced 100-1000 folds 
during acute phase responses. 
 In vitro studies have shown that CRP activates the entire recruitment cascade of 
white blood cells via inducing the release of ICAM-1, VACM-1, selectin E, and MCP-1 
[11, 12]. In such a case, endothelium enters into a “proinflammatory” state and initiates 
atherogenesis. In another study, CRP was implicated in endothelial dysfunction, 
characterized by impaired NO production and vasoreactivity [13]. In addition, CRP could 
also induce TF expression which is the key molecule in the coagulation cascade [14]. 
Furthermore, CRP was recently reported to induce MMP-1 and MMP-10 which could 
cause plaque instability [15]. To date, CRP is accepted as a direct risk factor of CAD 
because of its wide effects on atherogenesis. As another acute phase protein, SAA shares 
many characters with CRP. Both of them could be highly induced under inflammatory 
stimuli and in acute myocardial infarction (AMI) patients [9]. However, compared to 
CRP, SAA was less studied, especially its effects in atherosclerosis. 
 
1.4  SERUM AMYLOID A (SAA)  
1.4.1  The SAA family 
 The serum amyloid A (SAA) family is known to contain a number of 
differentially expressed apolipoproteins which are synthesized primarily by the liver and 
can be divided into two main classes based on their responsiveness to inflammatory 
stimuli. Acute-phase serum amyloid A (A-SAA) is the archetypal vertebrate major acute 
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phase protein (APP). Acute-phase proteins are a class of proteins whose plasma 
concentrations increase (positive acute-phase proteins) or decrease (negative acute-phase 
proteins) by at lease 25 percent in response to inflammation [16]. A-SAA is induced from 
resting levels by more than 1000-folds during bacterial infection, tissue damage and 
inflammation. The plasma concentration of A-SAA can exceed 1 mg/ml [17-19]. 
Constitutive SAA (C-SAA) has been described in two species, human [20] and mouse 
[21]. Unlike the A-SAAs, the C-SAAs are at most minimally induced during the acute-
phase response. Multiple SAA genes and proteins have been described for several 
mammalian species including human, mouse, hamster, rabbit, dog, mink, cow, sheep and 
horse [22-24]. The high degree of conservation of the SAA genes and proteins implies 
that they are likely to have important biological functions. 
 The human SAA family comprises four members, which have been subject to the 
most comprehensive analyses. The human SAA1 and SAA2 genes encode A-SAAs. 
These two genes have almost identical sequences and organizations, suggesting that the 
A-SAA genes have been subjected to recent gene conversion (i.e. homogenizing) events 
within each evolutionary lineage [22]. They are coordinately induced during the acute-
phase response and their mature protein sequences share greater than 90% identity. 
Among the two human A-SAAs, SAA1 is the dominant isotype, which consists of at least 
five allelic variants, while less have been reported for SAA2 [25]. The human SAA3 gene 
is a pseudogene because of a single base insertion in exon 3 which produces a frameshift 
and, consequently, generates a down-stream stop signal at codon 43 [26, 27]. No mRNA 
or protein product specified by human SAA3 has been identified. The human SAA4 gene 
is the only constitutively expressed gene in human SAA family. The human SAA4 
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protein sequence shares only 53% and 55% identities with human SAA1 and SAA2, 
establishing that the C-SAA constitute a distinct branch of the SAA family. 
 
1.4.2  Structure of human SAA proteins 
 All of the SAA genes described to date share a four-exon three-intron 
organization which is characteristic of many other apolipoproteins [28]. The mature SAA 
proteins range in size from 104 to 112 amino acids and are derived from primary 
translation products with 18-amino acid leader peptides (Fig. 2). Early work based on 
predictive methods suggested that SAA is likely to contain two regions of α–helix and β-
sheet [29]. In addition, several regions of mammalian A-SAA proteins that are important 
in facilitating the beneficial roles of SAA during inflammation have been identified. In 
vitro study indicated that the amyloidogenic region is within the first 10-15 N-terminal 
amino acids [30]. The lipid binding region of SAA resides within the first 11 N-terminal 
amino acids [31]. The region between residues 29 and 42 is the extracellular matrix 
(ECM)-like binding region, which suggests a role of SAA in inhibiting immune cell 
migration towards inflammatory sites and, perhaps, metastatic processes in vivo [32]. 
Evidence of A-SAA involvement in platelet aggregation is provided by its modulation of 
the induction of prostaglandin I2 (PGI2), a potent antiaggregation agent; this is mediated 
by the first 14 N-terminal amino acids of SAA [33]. A putative calcium-binding 
sequence, GPGG, between residues 48 and 51, is conserved in all SAA sequences 
identified to date [29]. Although relatively few functional studies of the C-terminus of 




Figure 2. The structure of human SAA protein. The 18-amino acid signal peptide is 
shown (-18 to 0) together with the 104 mature protein (1-104). The most frequently 
observed C-terminus of the amyloid A protein is indicated at residue 76. Regions of 
potential functional importance are indicated by underlining in color, while structurally 
important regions are indicated by shading/hatching; both are discussed in the text. Sites 
delimiting sequences encoded by exons 2/3 and 3/4 are indicated (exon 1 contains only 5’ 
untranslated region) (Adapted from Ref. [35]). 
 
1.4.3  Expression and induction of SAA 
 SAA is mainly synthesized in the liver following inflammatory stimuli, although 
induction of SAA synthesis has also been reported in adipocytes, intestinal epithelial 
cells, myocytes and macrophages [36-39]. Within the first 24 to 36 hours after infection 
or injury, the blood concentration of SAA can increase by as much as 1000-fold over 
basal level, reaching a concentration of 80 µM or 1 mg/ml [40].  SAA is also catabolized 
in the liver [41], has a much shorter half-life of 1 day [42] and is cleared from the plasma 
more rapidly than other high density lipoprotein (HDL) apoproteins such as 
apolipoprotein A-I (ApoA-I)  which has a half-life of 4-6 days [43, 44]. During an acute-
phase response or chronic inflammation, the capacity of the liver to degrade SAA 
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decreases, by 14% and 31% respectively [45], thereby contributing to the elevated 
circulating SAA levels observed under these conditions. 
 SAA mRNA and protein synthesis are induced in vivo during the inflammatory 
response to challenges such as tissue injury, infection and trauma in all vertebrate species 
(Fig. 3). These challenges induce the pro-inflammatory cytokine cascade. Expression of 
SAA is primarily regulated at the transcriptional level. Cytokines such as IL-1, IL-6, and 
tumor-necrosis factor α (TNFα), alone or in combination, act by binding to their 
respective receptors. As a consequence, induction of a series of transcription factors 
(CCAAT/enhancer binding proteins, NF-кB, and SAF-1), either by activation of resident 
pools of inactive factors in the cytoplasma and/or by increased factor biosynthesis, 
occurs. Alternatively, post-transcriptional regulation of human SAA genes has been 
reported [36]. Glucocorticoids, which are also released during inflammation, have been 




Figure 3. Induction of SAA during the acute-phase response. The flow diagram 
represents the induction of the acute-phase response in tissues by inflammatory stimuli 
leading to recruitment of macrophages and subsequent cytokine production. These cause 
changes in transcription factor availability in different tissues which result in increased 
SAA expression and consequently increased protein concentrations. The production of 
glucocorticoids by the adrenal cortex is upregulated by inflammatory cytokines and 




1.4.4  Functions of SAA 
 
 The SAA proteins have been highly conserved through evolution [22-24], and 
this, together with the dramatic induction of SAA expression in response to potentially 
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life-threatening physiological challenges, indicates a critical protective role in the acute-
phase response.  
 
1.4.4.1 Immune-related functions 
 SAA has been reported to induce ECM-degrading enzymes, such as collagenase, 
stromelysin, matrix metalloproteinases 2 and 3. These proteins are important for repair 
processes after tissue damage [49-51]. However, prolonged expression of SAA, and the 
consequent long-term production of these enzymes, may contribute to degenerative 
diseases such as rheumatoid arthritis. In vivo studies have provided convincing evidence 
that SAA can act as a chemoattractant for immune cells such as monocytes, 
polymorphonuclear leukocytes, mast cells and T lymphocytes [52-56]. If SAA has this 
property in vivo, its local production would result in the active recruitment of these cell 
types to inflammatory sites and the augmentation of local inflammation. Furthermore, 
several studies have reported induced expression and secretion of pro-inflammatory 
cytokines by SAA [55, 57]. Taken together, the above suggest that SAA may have 
cytokine-like properties.  
 
1.4.4.2 Anti-inflammatory roles 
 During an acute phase response, SAA constitutes 2.5% of the total protein 
produced in liver, and its plasma levels could be increased by as much as 1000- fold over 
the basal level, suggesting a beneficial role of SAA in host defense. SAA was implicated 
in the suppression of in vitro immune responses to antigens by affecting T cell-
macrophage interactions and helper T lymphocyte function [58-60]. Human SAA was 
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subsequently found to be a potent inhibitor of lymphocyte, HeLa and MRC5 cell function 
[61]. A potential feedback relationship between SAA and immunoregulatory cytokines 
was proposed based on the observation that SAA inhibits IL-1-induced and TNF-induced 
fever in mice [62]. Platelet aggregation has also been reported to be inhibited by SAA 
[63, 64]. SAA modestly induces prostaglandin I2 which is also an anti-aggregation agent 
[33]. As both platelets and the range of mediators released by them upon activation are 
involved in inflammatory and thrombotic processes, these findings suggest that SAA may 
act to down-regulate such pro-inflammatory events during the acute-phase response. 
SAA has also been reported to bind to neutrophils and, like other apolipoproteins such as 
ApoA-I, inhibit the oxidative burst response, suggesting that it may help prevent 
oxidative tissue damage during inflammation [65, 66]. 
 
1.4.4.3 SAA, amyloid A protein and amyloidosis 
 SAA is the serum precursor of amyloid A protein [67, 68], which is the principal 
component of the amyloid deposits found in the heterogeneous group of disorders, the 
amyloid A amyloidosis [69]. The predominant amyloid A protein type found in 
amyloidotic tissues corresponds to the N-terminal two thirds of SAA, the first 76 residues 
of mature human SAA [67]. However, both smaller and larger amyloid A protein types, 
45-95 residues, have also been found [70-73]. Multiple proteolytic cleavage events could 
be involved in the processing of SAA as it appears to be degraded first into an 
intermediate product with the same size and antigenic properties as amyloid A protein 
and is subsequently processed further. Amyloid A amyloidosis may therefore be the 
result of the incomplete digestion, and consequent accumulation, of amyloidogenic 
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intermediate peptides of SAA. A large number of cell-associated and serum proteases 
have been implicated in the degradation of SAA, which include serum serine proteases, 
elastase, collagenase, stromelysin and cathepsin B, D, G [74-79]. SAA is probably 
degraded after its disassociation from HDL, as full-length SAA can be found in amyloid 
fibrils [80-82]. Furthermore, lipid-free SAA can be degraded in vitro to form fibris [83]. 
In addition, SAA degradation in vivo is inhibited by lipoproteins, in particular HDL [41, 
74], and different plasma clearance rates of SAA and ApoA-I also suggest that SAA is 
not associated with HDL when it is degraded [44, 74].  
 
1.4.4.4 Lipid-related functions 
 SAA exists predominantly in the plasma HDL fraction (>90%) [84], which is the 
class of lipoproteins particles that play an important role in the prevention of 
atherosclerosis by both mediating reverse cholesterol transport and inhibiting the lipid 
(LDL) oxidation that promotes foam cell formation [84, 85]. As a result, the association 
of SAA with HDL during acute inflammation may alter HDL metabolism and cholesterol 
transport and promote a pro-atherogenic phenotype [86-88]. Several enzymes involved in 
cholesterol metabolism, including lecithin-cholesterol acyltransferase (LCAT), group-IIa 
secretory phospholipase A2 (sPLA2-IIa) and neutral cholesterol ester hydrolase (nCEH), 
are affected by induction of SAA during the acute-phase response. Under normal 
physiologic conditions, ApoA-I is the main apolipoprotein of HDL [89]. However, during 
the acute-phase response, SAA becomes the major HDL-associated apolipoprotein and 
the particle becomes depleted of ApoA-I [90]. As HDL is the site of cholesterol 
esterification which occurs through the action of LCAT, which in turn, requires ApoA-I 
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as an activating cofactor [91]. The relative lack of ApoA-I on SAA-enriched HDL (acute-
phase HDL) during inflammation may account for the positive correlation observed 
between plasma SAA and unesterified cholesterol levels, and the negative correlation 
with LCAT activity [88]. sPLA2 is made by vascular smooth muscle cells [92] and is also 
found in human atherosclerotic lesions [93]. Human acute-phase HDL (SAA-enriched 
HDL) was found to be two to three folds more susceptible to hydrolysis by sPLA2 than 
normal HDL [94]. Furthermore, SAA enhances the activity of sPLA2 [95] and 
overexpression of sPLA2 in transgenic mice can suppress HDL levels by 30% [96]. 
Consequently, the enhanced hydrolysis of acute-phase HDL by sPLA2 appears to be 
mediated by SAA itself. 
 Two main hypotheses have been proposed regarding the role of SAA in 
modulating cholesterol transport during inflammation based on the experimental data. 
SAA, as part of HDL, substantially increases the binding affinity of HDL for 
macrophages. Macrophages from animals with inflammation had a 5-fold increase in the 
number of binding sites for HDL/SAA relative to macrophages obtained from normal 
mice [86]. These observations suggest that SAA alters reverse cholesterol transport to 
allow delivery of lipid, particularly cholesterol, via HDL to peripheral cells that may have 
an increased requirement for cholesterol to facilitate tissue regeneration at inflammatory 
sites. On the other hand, SAA enhances the uptake of HDL/SAA by macrophages [97] 
and rapidly prompts the export of cellular cholesterol from macrophages laden with 
cholesterol [98, 99]. At sites of tissue injury, macrophages are cholesterol-laden because 
they would have ingested cell membrane debris, which is rich in cholesterol [100]. Thus, 
  37
SAA is indicated to facilitate removal of the large quantities of cholesterol liberated at 
sites of tissue damage during inflammation.  
 The ability of SAA to promote cholesterol efflux resides in SAA and not in other 
apolipoproteins [98, 99, 101, 102]. Increased efflux appears to result from the ability of 
SAA, or peptides derived from SAA, to regulate the intracellular activities of both 
acylCoA:cholesterol acyl transferase (ACAT) and neutral cholesterol esterase (CEH) [98, 
99]. ACAT esterifies cholesterol for storage and CEH de-esterifies cholesterol for export. 
SAA inhibits ACAT and enhances CEH activities, thereby driving the balance from 
stored to transportable free cholesterol. Regulation of ACAT and CEH by SAA was also 
observed in postnuclear homogenates and with purified pancreatic neutral CEH, 
indicating SAA or SAA peptides act directly within cells and not through a cell signaling 
pathway [101, 102]. SAA has also been shown to promote cholesterol as well as 
phospholipids efflux in an ABCA1-dependent manner [103]. Lipid-poor or lipid-free 
apolipoproteins function as cholesterol acceptors for ABCA1-dependent efflux in a 
manner requiring their binding to cells, probably through direct interactions with 
ABCA1, which initiates cholesterol efflux [104]. It is thus likely that in ABCA1-
dependent cholesterol efflux, SAA functions similarly to other apolipoprotein acceptors 
that contain amphipathic helices, which are thought to be crucial for acceptor function. 
Thus, SAA may enhance cholesterol efflux both by functioning as an acceptor and 





1.4.5  Receptors for SAA 
The mechanisms responsible for SAA-induced effects require SAA uptake into cells. 
SAA uptake into macrophages and a slow delivery to lysosomes has been described but 
the uptake mechanisms and receptors involved have not been defined [105, 106]. Several 
potential receptors for SAA have been postulated, including scavenger receptor B-I (SR-
BI) and its human orthologue CLA-1, receptor for advanced glycation end products 
(RAGE), formyl peptide receptor-like 1(FPRL-1), toll-like receptors (TLRs) and hepatic 
expressed Tanis receptor. 
 
1.4.5.1 SR-BI 
 Scavenger receptor SR-BI, is an HDL receptor that mediates cellular uptake of 
cholesterol ester from HDL by a mechanism known as selective lipid uptake [107, 108]. 
SR-BI-dependent selective lipid uptake in the liver plays a key role in HDL cholesterol 
clearance, thereby facilitating reverse cholesterol transport from the periphery cells to the 
liver. The receptor exhibits a broad ligand binding specificity and binds low density 
lipoprotein, very low density lipoprotein, and oxidized lipoproteins in addition to HDL 
[108]. SR-BI also binds anionic phospholipids as well as the apolipoproteins A-I, A-II, C-
III, and E, either as lipid-bound or as free apolipoproteins. In addition to mediating 
selective uptake, SR-BI facilitates the efflux of cellular free cholesterol to HDL. It has 
been reported that SAA is a high affinity ligand for SR-BI that exerts an inhibitory effect 
on HDL binding and selective lipid uptake [109]. SAA has been reported to promote 
cellular cholesterol efflux via SR-BI [110]. However, the lipidation status of SAA seems 
to be a critical factor governing its cholesterol acceptor properties [111].  
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1.4.5.2 FPRL-1 
 In vitro studies have provided compelling evidence that SAA can act as a 
chemoattractant for such immune cells as monocytes, polymorphonuclear leukocytes, 
mast cells, and T lymphocytes [52, 53, 56]. Chemoattractants, such as N-formyl-
methionyl-leucyl-phenylalanine (fMetLeuPhe) and the chemokines, act by binding seven-
transmembrane-spanning G-protein-coupled receptors [112]. The first clue to the identity 
of the SAA receptor came from experiments in which SAA selectively induced calcium 
mobilization and a migratory response in human embryonic kidney (HEK) cells 
overexpressing FPRL-1, thus establishing SAA as the first naturally occurring 
chemotactic ligand for the earlier orphan FPRL-1 [113]. Since then, several papers have 
presented evidence that SAA binds to such a receptor [114, 115]. The hallmark of the 
interaction between chemokine and their receptors via G-protein-dependent pathways is 
Ca2+ mobilization and protein kinase C activation. SAA binding is characterized by some 
of the same phenotypic effects. Protein kinase C appears to be involved in the SAA 
signaling pathways that result in monocyte recruitment, and, on binding, SAA transiently 
induces monocyte intracellular Ca2+ levels from extracellular sources. Therefore, it is 
probable that a G-protein is involved in SAA chemotaxis [114]. Furthermore, as the 
chemotactic effects mediated by SAA are pertussis toxin sentsitive, they probably involve 
the Gi subset of G-protein. The participation of a Gi-protein in SAA chemotaxis has 
subsequently been confirmed in human mast cells, which are normally resident in tissues 





 Recently, the receptor for advanced glycation end products (RAGE) has been 
identified to bind SAA [116]. This multiligand receptor of the immunoglobulin 
superfamily also binds, in addition to nonenzymatically glycated adducts, the β–sheet 
fibrils characteristic of amyloid, pro-inflammatory cytokine-like mediators of the 
S100/calgranulin family, and amphoterin, a nuclear protein sometimes found in the 
extracellular matrix [117]. Activation of cell-surface expressed RAGE by extracellular 
ligands results in a specific signaling cascade ultimately leading to the activation of NF-
кB and MAPK. Increased expression of RAGE is associated with a number of 
pathological conditions with high SAA concentrations. RAGE has been reported to bind 
human SAA1 and to promote expression of monocyte tissue factor via activation of NF-
кB through ERK and p38 MAPK pathway [116]. SAA also binds to sRAGE [116], the 
soluble and extracellular form of RAGE. Thus, sRAGE may be a promising therapeutic 
target to prevent vascular damage as a consequence of chronic inflammatory conditions 
by acting as a decoy for circulating RAGE ligands [117]. Indeed, preincubation of SAA 
with sRAGE prevented SAA-induced IкBα degradation. Most importantly, incubation of 




 Recent findings revealed that SAA could act as an endogenous agonist for the 
toll-like receptor 4 (TLR4) [119]. SAA stimulated macrophage production of nitric oxide 
radical in a TLR4-dependent manner that requires phosphorylation of ERK and p38 
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MAPK pathway [119]. Macrophages from C3H/HeJ and C57BL/10ScCr mice lacking 
this functional receptor complex (associated with innate immunity) did not respond to 
SAA stimulation. TLR2 has also been reported to involve in NF-кB activation, a process 
that promotes phosphorylation of all three major MAPK, ERK, p38 and JNK, 
respectively [120]. A neutralizing antibody against TLR2 significantly reduced SAA-
stimulated NF-кB activation in TLR2 overexpressing HeLa cells. SAA-induced 
expression of the two anti-inflammatory cytokines IL-10 and IL-1 receptor antagonist 
was completely abrogated in bone marrow-derived macrophages from tlr2-/- mice. SAA 
was shown to induce NO production through ERK1/2 and p38 pathway and this 
induction was dependent on functional TLR4 [119]. The researchers from another group 
also reported that SAA-induced G-CSF expression and neutrophilia were critically 
dependent on TLR2 [121]. All these data supported that SAA might be an endogenous 
ligand to TLRs. 
 
1.4.5.5 TANIS 
 Another SAA binding receptor, identified by yeast two-hybrid screening, is 
TANIS [122]. TANIS, a membrane selenoprotein predicted to have a single 
transmembrane region close to its N-terminus, was shown to be regulated by glucose and 
is differentially expressed in type-2 diabetes. Therefore, it provides a link among 





1.4.6  SAA and cardiovascular disease 
 The characterization of SAA as both an inflammatory protein and an 
apolipoprotein generate increased interest in CAD research as both are involved in 
atherogenesis. SAA is implicated to have both beneficial and harmful effects in the 
inflammatory process. Accumulating clinical evidence shows that SAA is associated with 
CAD. Plasma SAA levels increase in response to tissue damage, causing consequent 
inflammation. It is therefore, not surprising that SAA concentration is elevated (100- to 
500-fold) in patients who have suffered a myocardial infarction [123]. It has been 
observed that modestly elevated SAA (4- to 8-fold) is an indication of a poor prognosis in 
patients with unstable angina prior to objective evidence of a myocardial infarction [124]. 
SAA levels also increase with age, when cardiovascular disease increases with frequency 
[125]. Long-standing histological observations of atherosclerotic plaques indicate that 
inflammation is an ongoing process in these lesions. Therefore, active atherosclerotic 
lesion could be the stimulus for raised plasma SAA levels, but the increase is a fraction of 
that seen during significant tissue injury (4- to 8-fold versus 100- to 1000-fold, 
respectively). It is in this context that very modestly elevated plasma SAA serves as a 
prognostic indicator of cardiovascular disease. Elevated plasma SAA may identify 
patients with more active vascular disease, even in those individuals in whom the process 
is clinically silent. Thus, acute-phase SAA may be a product of the inflammation caused 
by atherosclerotic lesions, rather than a cause of the plaques. The potential beneficial 
roles of SAA include its involvement in the reverse cholesterol transport and possibly 
extracellular lipid deposition at sites of inflammation and tissue repair [97]. Reverse 
cholesterol transport involves the removal of excess cholesterol from peripheral tissues, 
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including foam cells of the arterial wall, and its delivery to the liver for biliary excretion. 
Cholesterol efflux is a crucial process regulating the cholesterol homeostasis of an 
organism and is thus an important therapeutic target for the prevention and reversal of 
atherosclerosis [126]. Cholesterol efflux is the only mechanism by which cells can limit 
or reverse the cellular cholesterol accumulation [127]. Therefore, the physiological role 
of SAA in atherosclerosis is not conclusive.  
 
1.5  PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ (PPARγ) 
1.5.1  PPAR family 
 The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear 
receptor proteins that serve as transcription factors regulating the expression of genes. 
PPARs possess a conserved DNA binding domain and a ligand binding domain which are 
characteristics of nuclear receptors [128-130]. The central DNA binding domain consists 
of two zinc finger motifs that mediate sequence-specific recognition of hormone response 
elements in direct target genes (Fig. 4). PPARs heterodimerize with retinoid X receptors 
(RXRs) and bind to specific PPAR response elements (PPRE) of the target genes. The C-
terminal ligand binding domain (LBD) determined the ligand specificity of each receptor 
and mediates ligand-regulated interactions with other proteins that act as effectors of 
transcription activation and/or repression.  
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Figure 4. Classical structure of PPAR with the zinc fingers which interact with 
specific response elements located in the target genes (Adapted from Ref. [131]). 
 
 
 Three isoforms of PPARs (α, β/δ, γ) have been identified, displaying distinct 
physiological and pharmacological functions depending on their target genes and their 
tissue distribution [132, 133]. Indeed, the activation of PPARα, by both natural ligands 
such as fatty acids and eicosanoid derivatives or synthetic ligands (lipid-lowering 
fibrates), regulates lipid homeostasis [134]. PPARα is highly expressed in liver, kidney, 
heart and skeletal muscle and has been shown to be the biological target for the fibrate 
class of lipid-lowering drugs. PPARβ/δ is one of the most widely expressed members of 
the PPAR family [128]. Until recently, the function of PPARβ/δ remained elusive, but 
recent results have shown that PPARβ/δ also plays a key role in lipid metabolism, as it 
regulates serum lipid profiles and fatty acid β-oxidation in muscle and adipose tissue 
[135]. Synthetic ligands of PPARβ/δ are at the moment in preclinical phases of 
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development [135]. As PPARγ is a very important subject in my study, I will discuss its 
activation and functions in separate sections. 
 
1.5.2  PPARγ activation 
 Nuclear receptors can be activated in ligand-dependent and ligand-independent 
mechanisms. PPARγ, like other nuclear receptors, binds lipophylic ligands and regulates 
transcription upon ligand binding. PPARγ could be activated by endogenous ligands such 
as a number of naturally occurring unsaturated fatty acids, arachidonic acid metabolites, 
fatty acid-derived components of oxLDL, and synthetic ligands. Endogenous PPARγ 
ligands include 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) [136, 137] and 15-HETE 
[138], 9- and 13-HODE [139]. All of these endogenous ligands can activate PPARγ in 
vitro. Synthetic ligands include thiazolidinedione (TZD), a group of compounds 
comprising troglitazone, rosiglitazone, pioglitazone and ciglitazone, and phenylacetic 
acid derivatives [140]. 
 Peroxisome proliferators response elements (PPREs) are usually located upstream 
of PPARγ target genes. PPREs consist of a direct repeat of the nucleotide sequence 
TGA(A/C)CT separated by a single nucleotide. PPARγ binds to PPREs as heterodimers 
with retinoid X receptor (RXR). PPARγ/RXR heterodimers recruit a protein complex that 
consists of co-activators or co-repressors to direct transcriptional activation or repression, 
respectively. In the absence of ligands, PPARγ/RXR heterodimers bind to PPREs in a 
conformation that favors the binding of co-repressor molecules leading to the inhibition 
of transcriptional activity. Potential co-repressor candidates include NCoR and SMRT 
[141-144]. Upon ligand binding, the heterodimers are activated and undergo 
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conformational changes that promote co-activator recruitment and positive regulation of 
gene expression. The term “activation” represents an alteration in the three dimensional 
structure of the receptor complex such that it is able to regulate gene expression. The 
physical alteration that is initiated by ligand binding may include events such as loss of 
heat shock proteins and chaperones, nuclear translocation, and protein turnover. 
Conformational changes of PPARγ have been observed using limited proteolysis [145].  
Activation of PPARγ is closely related with its functions. 
 
1.5.3  Functions of PPARγ 
 In the decades since it was first cloned [146], an extensive body of literature has 
evolved relating to the biology of PPARγ. Differential promoter usage and alternative 
splicing of the gene generate three mRNA isoforms: PPARγ1 and PPARγ3 mRNA 
encode the same protein product; the PPARγ2 isoform contains an additional 28 amino 
acids at its N-terminus that confers a tissue-specific transactivation function.  
 PPARγ1 exhibits widespread expression, albeit at low levels, whilst PPARγ2 and 
PPARγ3 are highly expressed in adipose tissue. Systemic deletion of the PPARγ gene 
results in embryonic lethality attributable to essential roles in adipose, kidney, and 
placental development [147]. Indeed, the receptor plays a critical role in fat cell 
differentiation, inducing the expression of adipocyte-specific genes, and promoting the 
formation of mature lipid-laden adipocytes [148-150]. Recent studies with mice 
genetically engineered to lack PPARγ have confirmed its critical role in the development 
of both white and brown adipocytes in vivo [147, 151, 152], and the clinical phenotypes 
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of subjects with PPARγ gene mutations suggest a similar role in the regulation of human 
adipose tissue mass [153, 154]. 
 PPARγ plays a crucial role in glucose homeostasis and is the molecular target of a 
class of insulin-sensitive drugs referred to as thiazolidinediones [155]. Consistent with 
this, a number of PPARγ polymorphisms are linked with features of the metabolic 
syndromes including insulin resistance, hypertension, and obesity. Dominant-negative 
mutations in PPARγ have been shown to cause severe insulin resistance [156]. The 
analysis of mice with deletions of PPARγ in specific tissues indicates major roles in 
controlling insulin resistance in adipose tissue, with contributions also observed in liver 
and skeletal muscle [57, 157-159]. The mechanisms by which PPARγ influences insulin 
action have been intensively studied, and several potentially important targets of 
regulation have been established. Activation of PPARγ induces the expression of the 
insulin-dependent glucose transporter GLU4 [160], enhances the release of free fatty 
acids from chylomicrons and VLDL [161], upregulates genes involved in intracellular 
fatty acid transport, synthesis, and esterification [148, 162], and increases the expression 
of adiponectin [163, 164]. 
 A role for PPARγ in the regulation of inflammation and immunity was initially 
proposed by the findings that it is expressed in macrophages and inhibits the expression 
of a number of proinflammatory genes, including TNFα, IL-1β, iNOS, and gelatinase B 
[165, 166]. A large number of inflammatory responses have been shown to be subject to 
negative regulation by PPARγ agonists [167, 168]. PPARγ ligands inhibited 
transcriptional responses of primary macrophages to bacterial lipopolysaccharide in a 
PPARγ-dependent manner [169]. 
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 The results from in vitro studies of the effects of PPARγ agonists on cholesterol 
homeostasis suggested both atherogenic and anti-atherogenic influences. PPARγ was 
found to stimulate transcription of the CD36 gene [139, 170], which is a macrophage 
scavenger receptor that involves in macrophage foam cell formation and the development 
of atherosclerosis in mice [171]. In conjunction with the discovery that PPARγ can be 
activated by 9- and 13-HODE present in oxLDL, oxLDL lipids would induce the activity 
of PPARγ, leading to increased expression of CD36, which in turn would increase the 
uptake of oxLDL [139, 170]. This cycle would potentially promote foam cell formation 
and atherosclerosis. With respect to cholesterol efflux pathways, PPARγ was shown to 
induce the expression of liver X recptor α (LXRα) and thereby enhance ABCA1-
dependent cholesterol efflux to apoA-I and ABCG1-dependent cholesterol efflux to HDL 
[172-174] (Fig. 5). The cytochrome P450 enzyme Cyp27, which catalyzes production of 
the LXR agonist 27-hydroxy-cholesterol, has been demonstrated to be activated by 
PPARγ [175]. Cyp27 may therefore serve as an integrator of the PPARγ cholesterol 
efflux pathway in macrophages by generating ligands that activate LXR (Fig. 5). 
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Figure 5. Regulation of cholesterol efflux pathways in macrophages by PPARγ and 
LXRα. LXRα agonists stimulate the expression of ABCA1, which facilitates the 
efflux of cholesterol to lipid-poor apolipoprotein A-I (apoA-I), and ABCG1, which 
facilitates the efflux of cholesterol to HDL. PPARγ agonists can induce the expression 
of LXRα, therefore stimulating cholesterol efflux to apoA-I in an LXR-dependent 
manner. PPARγ ligands also directly activate ABCG1, enabling LXR-independent efflux 
to HDL. PPARγ has also been shown to inhibit cholesterol esterification in cholesterol-
loaded macrophages. This effect is not attributed to changes in ACAT expression and 
may result from altered cholesterol trafficking within the cell (Adapted from Ref. [176]). 
 
 Clinical studies found that treatment of diabetic patients with thiazolidinediones 
inhibited carotid intimal thickening [177, 178]. Investigations of the effects of PPARγ 
agonists in hypercholesterolemic male mice have consistently demonstrated anti-
atherogenic effects despite an increased expression of CD36 in atherosclerotic lesions 
[179-181]. PPARγ agonists improved insulin sensitivity in these studies and inhibited the 
expression of inflammatory markers in the artery wall. Interestingly, in the one study 
using female mice, PPARγ agonists were not effective at inhibiting the development of 
atherosclerosis [179]. These data are consistent with the idea that PPARγ agonists can act 
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to promote both atherogenic and anti-atherogenic effects, with the net outcome being 
influenced by additional factors such as hormonal status. 
 PPARγ is an important transcription factor that plays roles in an ever increasing 
list of regulatory mechanisms in metabolism, inflammation, endothelial function, cancer, 
atherosclerosis, and bone morphogenesis. Additionally, PPARγ has gained instant 
medical relevance through the fortuitous discovery that members of the TZD class of 
drugs can be used to improve insulin sensitivity in type 2 diabetic patients and are high-
affinity ligands for PPARγ [137]. PPARγ can also be used as a model transcription factor 
to study mechanisms of transcriptional regulation. For these reasons PPARγ has always 
been in the spotlight of intense research. 
 
1.6  MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) 
1.6.1  General features  and biological functions of MAPK  
 Mitogen-activated proteins kinase (MAPK) signal transduction pathways are 
among the most wide-spread mechanisms of eukaryotic cell regulation. All eukaryotic 
cells possess multiple MAPK pathways that are activated by distinct set of stimuli, 
allowing the cells to respond coordinately to multiple and divergent inputs. These 
signaling pathways control essential processes in all eukaryotic cells, including gene 
transcription, protein translation, cytoskeletal remodeling, endocytosis, cell metabolism, 
cell proliferation and survival. MAPKs are serine/threonine protein kinases that can 
phosphorylate their target proteins [182]. To date, six major subfamilies have been 
identified: extracellular-signal regulated kinases 1/2 (ERK1/2), p38 MAPKs, Jun N-
terminal kinases/stress-activated protein kinases (JNKs/SAPKs), ERK7/8, ERK3/4 and 
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ERK5 [182-187]. There are splice variants for several of the MAPK proteins that increase 
the diversity of the cascade. The most extensively studied groups are ERK1/2, JNKs and 
p38 kinases.  
 Although each MAPK is unique, they share some common features, and have thus 
been grouped together in one family. A three-tiered signaling cascade is typical of these 
pathways. It consists of a set of three evolutionarily conserved, sequentially acting 
kinases: MAPK, MAPK kinase (MAPKK), and MAPK kinase kinase (MAPKKK), which 
is also called MAP3K or MEKK. MAP3Ks are Ser/Thr kinases that are activated by 
phosphorylation and/or their interaction with small GTP proteins of Ras/Rho family in 
response to extracellular stimuli. MAP3K activation results in phosphorylation and 
activation of downstream MAPKK, which is a dual specificity kinase and can 
phosphorylate MAPK. Once activated, MAPKs phosphorylate the target substrates on 
serine or threonine residues only if the amino acid residues are followed by proline [188]. 
These substrates could be transcription factors, other kinases or proteins like cytoskeletal 
proteins. The cellular responses regulated by MAPK pathways are very diverse, ranging 
from proliferation to differentiation, from apoptosis to cell survival. 
 
1.6.1.1 MAPK in cancer 
 Carcinogenesis and the development of cancer can be said to be a disorder of the 
signaling system. The ERK pathway is deregulated in approximately one third of all 
human cancers. Many components of this signaling pathway have been linked to cell 
proliferation. In the ERK pathway, the key point seems to be the Ras/Raf motif. The 
involvement of Ras in cancer has been known for a very long time [189]. Aberration 
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spans the whole pathway beginning from an aberrant receptor like epidermal growth 
factor receptor (EGFR) overexpression, Ras and Raf mutation to amplification of nuclear 
targets, most notably myc and activator protein 1 (AP-1) [189]. ERK signaling also plays 
a role in the disrupting the anti-proliferative effects of ligands such as transforming 
growth factor-β (TGF-β). Accumulating evidence also suggests that the expression of 
different feedback inhibitors of the ERK pathway is deregulated in cancer [190-192]. A 
role for the JNK pathway in tumorigenesis is supported by the high levels of JNK activity 
found in several cancer cell lines. JNK activity and phosphorylation of c-jun has been 
reported to play a critical role in Ras-induced tumorigenesis and Ras and c-jun cooperate 
in cellular transformation [193, 194]. Another important function of c-jun appears to be 
transcription repressor of p53 [195, 196]. Some studies showed that p38 functions as a 
tumor suppressor. These tumorsuppressive effects have been demonstrated to be 
mediated by activation of p53 and p53-dependent apoptosis [197].  
 
1.6.1.2 MAPK in cell cycle 
 The ERK1/2 pathway has emerged as a central regulator of cell proliferation by 
controlling both cell growth and cell cycle progression. Various mechanisms have been 
proposed to explain the role of ERK1/2 pathway in cell cycle progression. The most 
important targets are D-type cyclins and c-myc. Activation of the ERK pathway induces 
the D-type cyclins by up-regulating and activating the transcription factors involved in its 
synthesis. ERK1/2 may also control its expression at post-transcriptional level [198, 199]. 
c-myc is a transcription factor of the Myc family. It plays an important role in regulating 
cell growth, cell progression and apoptosis [200], exerts its functions by up-regulation of 
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certain genes involved in cell growth such as cyclin D [201] and p21 [202], ribosomal 
proteins and translation factors [203]. Activation of ERK stabilizes c-myc by 
phosphorylation [204-206]. p38 was reported to involve in cell cycle arrest and this effect 
is probably mediated by mitogen- and stress-activated protein kinases (MSKs) [207].  
 
1.6.1.3 MAPK in apoptosis 
 Although the ERK pathway is attributed to survival in most cell types, its 
activation is now also thought to contribute to apoptosis. ERK activation has been shown 
to be involved in death induced by many factors such as reactive oxygen species (ROS) 
[208], E. coli toxins [209], and zinc [210], and also by deprivation of survival factors 
[211]. The mechanism by which the ERK pathway mediates apoptosis remains poorly 
understood and seems to occur at different level of signaling. Previous study showed that 
promotion of cell death by ERK activation may result through suppression of Akt-
mediated survival signaling [211]. A role for JNK in apoptosis is well established [212]. 
One potential target of pro-apoptotic JNK signaling is the tumor suppressor p53. Binding 
to JNK was reported to destabilize p53 by promoting ubiquitin-mediated degradation 
[213]. Activation of p38 was observed in cells undergoing apoptosis induced by variety 
of agents. Studies showing the inhibition of p38 by caspase inhibitors suggested the role 
of p38 downstream of caspase activation. 
 Other than the functions mentioned above, MAPK pathway is also related to cell 




1.6.2  SAA and MAPK 
Recent studies have shown that SAA could activate MAPK pathways in cells 
from the vessel wall [119, 120, 214-220]. The receptors involved in the SAA-induced 
MAPKs activation are different. Toll-like receptor 2 (TLR2), human orthologue of the 
scavenger receptor class B type I (SR-BI), CD36 and LIMPII analogous-1 (CLA-1) and 
G-protein coupled receptor such as formyl peptide receptor-like 1 (FPRL1) were 
indicated to play a role in SAA-induced MAPKs activation [119, 120, 215-217, 219, 
220]. They are presented in Table 1 together with the possible cellular functions regulated 
by the MAPKs. Many of these studies have used inhibitors to assess the signaling and 
functions of SAA-induced MAPK activation. Therefore, to facilitate reading of Table 1, 














Table 1 SAA-induced signaling and cellular responses 
 

















---- IL-8 expression and 






HeLa 25 µg/ml ERK1/2, 
p38 
CLA-1 IL-8 production 









FPRL1 Apoptosis (Blocked 





HUVEC 20 µg/ml ERK1/2, 
p38, JNK 
FPRL1 Procoagulation, TF 
expression and TFPI 






HeLa 1 µM 
(~12 
µg/ml) 




He  2006 
[218] 
THP-1 1 µM 
(~12 
µg/ml) 












FPRL1 TNFα and IL-10 
production (Blocked 





THP-1 10 µg/ml ERK1/2, 
p38 
GPCR CCL20 production 






RA-FLS 1 µM 
(~12 
µg/ml) 





SAA 1 µM = 12 µg/ml 
 
Caco-2, human epithelial colorectal adenocarcinoma cells; CCL20, Chemokine (C-C 
motif) ligand 20; CLA-1, CD36 and LIMPII analogous-1; ERK 1/2, extracellular-signal 
regulated kinases 1/2; FPRL1, formyl peptide receptor-like 1; GPCR, G-protein coupled 
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receptor; HeLa, human cervical adenocarcinoma cell line; HUVEC, primary human 
umbilical vein endothelial cell; IL, interleukin; JNK, Jun N-terminal kinases/stress-
activated protein kinases; MAPK, mitogen-activated protein kinase; NF- кB, nuclear 
factor-kappa B; RA-FLS, rheumatoid arthritis fibroblasts; SAA, serum amyloid A; TF, 
tissue factor; TFPI, tissue factor pathway inhibitor; THP-1, human acute monocytic 
leukemia cell line; TLR-2, toll-like receptor 2; TNFα, tissue necrosis factor alpha; WISH, 
human amnion cell line. Information concerning the inhibitors mentioned here can be 
found in Table 2.  
 
Table 2 Characteristics of the inhibitors mentioned in Table 1 
 
Inhibitors Targets 








p38α and p38β MAPKs 
p38α and p38β MAPKs 
JNK MAPK pathway 
SP600125 
 






ERK 1/2, extracellular-signal regulated kinases 1/2; JNK, Jun N-terminal kinases/stress-
activated protein kinases; MAPK, mitogen-activated protein kinase; MKK, MAPK 
kinase; TLR-2, toll-like receptor 2. 
 
1.6.2.1 Endothelial cells 
Endothelial cells were used to investigate the effects of SAA on the MAPKs 
activation in several studies [120, 214-217]. SAA-induced ERK1/2 and p38 activation 
were reported in most of these studies. However, evidence that the JNKs were activated 
by SAA was scarce, suggesting that the JNK MAPK pathway may not be an important 
target of SAA in endothelial cells. SAA-induced MAPKs activation in endothelial cells 
leads to the expression and secretion of the inflammatory cytokines [120, 214, 215], 
initiation of the procoagulation [217] and apoptosis [216].  
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As an acute-phase protein, SAA secretion is a host response to dangerous signals 
and a clinical indication of inflammation. Some recent reports suggest that the biological 
functions of SAA might induce inflammatory cytokine expression and secretion.  The 
experimental data showed that SAA could induce IL-8 expression and secretion, which 
was dependent on ERK1/2 and p38 activation [214, 215]. SAA-dependent IL-8 
expression was inhibited by ERK1/2 and p38 inhibitors in these studies. NF-кB 
transcriptional activity was also enhanced by SAA through ERK1/2 pathway [120], 
which would further lead to the expression and secretion of some other inflammatory 
cytokines.  
SAA was involved in the procoagulation by inducing the expression of tissue 
factor (TF) and inhibiting the tissue factor pathway inhibitor (TFPI) [217]. The inhibition 
study confirmed that such effects were dependent on MAPKs activation. Surprisingly, all 
the three subfamilies of MAPKs were activated and contributed to such effects. One 
study has reported that SAA-dependent ERK1/2 and p38 phosphorylation in WISH 




ERK1/2 and p38 MAPK pathway have been clearly demonstrated to be activated 
by SAA in monocytes [119, 218, 219]. Most of the cellular effects associated with their 
activation have been related to the expression and secretion of the inflammatory 
cytokines such as IL-10, IL-12, TNFα and CCL20. These data indicate that SAA 
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potentially participates in the inflammatory process by virtue of its ability to activate 
inflammatory signaling in monocytes. 
 
1.6.2.3 Fibroblasts  
As observed in endothelial cells and monocytes, SAA also induces the production 
of pro-inflammatory cytokine, IL-6, in fibroblasts through the activation of p38 and JNK 
[220]. However, in this case, the implication of MAPK pathways is still not confirmed as 
there is only one study reported the involvement of p38 and JNK in fibroblasts.  
Plasma SAA levels increase dramatically in response to tissue damage or 
inflammation.  Evidence from recent studies has shown that increased SAA will stimulate 
the production and secretion of pro-inflammatory as well as inflammatory cytokines in 
endothelial cells, monocytes and fibroblasts [119, 120, 214, 215, 218-220]. Chronic 
production of such cytokines may result in pro-atherogenic inflammatory conditions and 
excessive proliferation and angiogenesis would participate in the development of 
atherosclerotic plaques, leading to vessel wall thickening and accelerate the atherogenic 
process. The observation that the thickening of blood vessels can be inhibited by MAPK 
inhibitors is consistent with the notion that SAA-induced MAPK activation participates 
in the development of atherosclerosis [221]. Accumulating evidence indicates that SAA 
potentially participate in the atherosclerosis by its ability to activate inflammatory 
signaling through MAPKs activation. Recent studies have also demonstrated that tissue 
factor (TF) could be markedly induced by some atherosclerosis risk factors such as tumor 
necrosis factor α (TNFα) and SAA. Conversely, native tissue factor pathway inhibitor 
(TFPI) degradation after thrombolysis may enhance procoagulation and leads to early 
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reocclusion after thrombolysis in myocardial infarction (MI). The data that SAA induces 
TF and inhibits TFPI expression in a MAPKs-dependent manner indicate that SAA may 
play a role in the initiation of coagulation, which is the major cause of atherosclerosis, 
based on the MAPKs activation. One study also linked SAA and MAPKs activation with 
endothelial cell apoptosis. Apoptosis occurs in all cells of the atherosclerotic plaque, 
becoming increasingly frequent and important as the plaque develops. Apoptosis 
contributes to plaque growth, lipid core development, plaque rupture and thrombosis. As 
there is only one study reporting such relationship among SAA, MAPKs and apoptosis, 
the possible impact of SAA on apoptosis remains obscure. 
 
1.7  NF-ĸB 
1.7.1  General features and biological functions of NF-ĸB 
Nuclear factor к B (NF-кB) signaling pathway regulates immune responses and is 
implicated in the pathogenesis of many inflammatory diseases. NF-кB induction is 
essential for the expression of a wide variety of immune-response genes. These include 
pro-inflammatory cytokines (TNFα, IL-1 and IL-6), chemokines (macrophage 
inflammatory protein-1α) and adhesion molecules (E-selectin and vascular cell adhension 
molecule-1), which collectively regulate the recruitment of immune cells to sites of 
infection [222]. TNFα and IL-1 stimulation of their respective receptors in turn strongly 
activates NF-кB, which plays an important role in amplifying and extending the duration 
of the innate immune response [223, 224]. Dysregulation of NF-кB can lead to the 
constitutive over-production of pro-inflammatory cytokines, which is associated with a 
number of chronic inflammatory disorders, including rheumatoid arthritis and Crohn’s 
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disease [225, 226]. NF-кB also plays an important role in regulating the expression of 
anti-apoptotic proteins and the cell-cycle regulator cyclin D1, which increase cellular 
survival and proliferation respectively [227, 228]. Consequently NF-кB has been 
implicated in cell transformation [228], and persistent NF-кB activation may explain the 
known causative link between chronic inflammation and certain types of cancer [229, 
230].  
The NF-кB family of transcription factors consists of five members in 
mammalian cells: RELA (also known as p65), REL (also known as c-REL), RELB, p50 
and p52, which can form homodimers or heterdimers. In unstimulated cells, NF-кB 
dimmers are inactive, since they are sequestered in the cytoplasm by interaction with 
inhibitory proteins termed IкBs [231]. Following cell stimulation, the IкB kinase complex 
phosphorylates IкB proteins on specific serine residues, which are proteolytically 
degraded by the proteasome, releasing associated NF-кB dimmers to translocate into the 
nucleus and modulate gene expression (Fig. 6). 
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Figure 6. Model of the generic NF-кB activation pathway. Various stimuli induce the 
phosphorylation (P) and subsequent polyubiquitination (Ub) of IкBs, which are then 
targeted for degradation by the 26 S proteasome. Associated NF-кB dimmers are thereby 
released to translocate into the nucleus, where they bind to the promoter regions of NF-
кB-responsive genes to modulate their expression. The transactivating capacity of nuclear 
NF-кB dimmers can also be regulated by phosphorylation (Adapted from Ref. [232]). 
 
 
Three distinct NF-кB activation pathways have been described. The canonical 
(classical) pathway is activated by a large number of stimuli, including proinflammatory 
cytokines, bacterial and viral products, and also stress-inducing stimuli such as γ-
radiation, ultraviolet light and oxidative stress. Activation of this pathway depends on the 
IKK complex, which phosphorylates IкB to induce its rapid degradation. This pathway is 
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essential for immune responses, inflammation and promoting cell survival. The 
alternative NF-кB pathway is activated by a limited number of agonists and is important 
for secondary lymphoid organogenesis, maturation of B-cells and adaptive humoral 
immunity. This pathway requires NF-кB binding kinase and IKK and induces the slow 
processing of p100 to p52, resulting in nuclear translocation of p52/RELB heterodimers. 
The p105 pathway is specifically involved in immune and inflammatory responses. 
Agonist activation of this pathway induces phosphorylation of the p105 PEST region by 
the classical IKK complex. This triggers p105 polyubiquitination and subsequent 
degradation, releasing p50 homodimers which undergo unclear translocation and 
positively or negatively regulate gene transcription [232]. 
 
1.7.2  SAA and NF-кB 
 Previous studies have shown that SAA could activate NF-кB in various cell types. 
Earlier studies found that SAA might play a role in inducing proinflammatory genes such 
as IL-8, IL-12 and IL-23 [214, 218]. Recent data showed that SAA could induce the 
expression of MMP-9, TNFα, IL-6, IL-10, TF and Chemokine (C-C motif) ligand 2 
(CCL2) in a NF-кB-dependent manner [115, 116, 219, 220, 233]. A latest study 
demonstrated that SAA induced IKK phosphorylation as well as the movement of p65, a 
component of NF-кB, from the cytoplasm to the nucleus. The EMSA experiment results 
indicated that the binding of NF-кB to the identified binding site on the sPLA2 (secretory 
phospholipase A2, group IIA) gene promoter was increased upon SAA stimulation [234]. 
SAA had also been suggested to stimulate angiogenesis, leukocyte recruitment and 
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matrix degradation in rheumatoid arthritis through a NF-кB-dependent signal 
transduction pathway [235].  
Many bacterial products can activate NF-кB. The identification of toll-like 
receptors (TLRs) as specific pattern recognition molecules and the finding that 
stimulation of TLRs leads to activation of NF-кB improved our understanding of how 
different pathogens activate NF-кB. TLRs recognize invariant microbial molecules, 
including components of the bacterial cell wall such as lipopolysaccharide (LPS) and 
microbial nucleic acids [236]. SAA has been postulated to be a ligand of TLRs. Therefore, 
there is a potential link among SAA, TLRs and NF-кB. However, the receptors between 
SAA and NF-кB activation remain obsecure. Some data supported that SAA-induced 
effects were through FPRL-1 [115, 217, 219, 233]. Some studies provided evidence that 
SAA-induced NF-кB was mediated by other receptors such as RAGE and TLR [116, 
121]. Whether these receptors are essential or dispensable for SAA-induced NF-кB 
activation in hepatocytes remains to be determined. A wide range of microbial pathogens 
could activate NF-кB through TLRs and SAA was identified to be a potential 
endogenous ligand for TLRs [119]. Whether SAA could activate NF-кB through TLRs 
also need to be explored. 
 
1.8  REVERSE CHOLESTEROL TRANSPORT  
An early hallmark of atherosclerosis is the accumulation of cholesterol-loaded 
macrophages (foam cells) in the intima of arteries. Numerous epidemiological studies 
have also demonstrated that plasma levels of high-density lipoproteins (HDL), and their 
major protein constituent apolipoprotein A-I (apoA-I)  are inversely correlated with the 
  64
risk of atherosclerosis [237]. HDL and apoA-I could exert diverse potentially 
atheroprotective functions. Previous evidence showed that they reduced oxidative 
damage, corrected endothelial dysfunction, inhibited inflammation and mediated reverse 
cholesterol transport [127]. The latter process involves the removal of excess cholesterol 
from peripheral tissues including foam cells of the arterial wall and its delivery to the 
liver for biliary excretion. The efflux of cholesterol mediated by HDL and its 
apolipoproteins is both a crucial process regulating the cholesterol homeostasis of the 
organism and an important therapeutic target for the prevention and reversal of 
atherosclerosis.  
For many years, the efflux of cholesterol was thought to occur primarily by 
passive aqueous diffusion from the cell surface onto various extracellular acceptors 
including HDL, LDL, albumin and protein-free unilamellar phospholipid vesicles. Net 
cholesterol efflux by this process requires a concentration gradient between the donor cell 
membrane and the various extracellular acceptor particles. Recently it has become clear 
that cholesterol efflux is a highly regulated process that is mediated by specific molecules, 
including ATP-binding cassette (ABC) transporters. ABC transporters form a large 
family of proteins involved in the cellular export or import of a wide range of substrate 
including ions, lipids, cyclic nucleotides, peptides and proteins. Two of them, ABCA1 
and ABCG1, play a pivotal role in mediating cellular efflux of phospholipids and 
cholesterol to lipid-free apoA-I and HDL, respectively (Fig. 7). 
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Figure 7. Mechanisms of cholesterol efflux from the arterial wall. On entering the 
sub-endothelial space, lipid-free or lipid-poor apolipoprotein A-I (apoA-I) can bind to the 
ABC transporter A1 (ABCA1) on the cell surface of macrophages in the arterial wall and 
promote efflux of free cholesterol and phospholipids from these cells. This results in the 
formation of nascent high-density lipoprotein (HDL) particles, which undergo further 
modification by the lecithin-cholesterol acyltransferase (LCAT) enzyme and develop into 
spherically shaped HDL2 (larger, less dense particles) or HDL3 (smaller, more dense 
particles), which, in turn, can act as acceptors for ABCG1-mediated cholesterol efflux 
from macrophages, resulting in further cholesterol enrichment of HDL, before returning 
to the circulation. Although inter-conversion of HDL subspecies is depicted as occurring 
in the arterial wall, it probably also occurs in the plasma (Adapted from Ref. [238]). 
 
1.8.1  ABCA1-mediated cholesterol efflux 
The human ABCA1 gene has been mapped to chromosome 9q31 and is composed 
of 50 exons, which encode 2261-amino-acid residues [239]. The ABCA1 protein is a full-
size ABC transporter containing two transmembrane domains of six alpha-helices and 
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two intracellular nucleotide binding domains. The ABCA1 has been identified as the 
cause of Tangier’s disease [240-242], a rare disease characterized by very low levels of 
plasma HDL due to rapid catabolism and accumulation of cholesterol and cholesteryl 
esters in macrophage foam cells in various tissues such as tonsils, liver and spleen. 
Patients with Tangier’s disease seem to experience moderately accelerated 
atherosclerosis. ABCA1 promotes the efflux of free cholesterol and phospholipids from 
cells to lipid-poor apoliprotein A-I (apoA-I) to generate nascent HDL particles. Lipid-
poor apoA-I interacts directly with ABCA1, possibly by binding to the two large 
extracellular domains of this transporter. This binding seems to constitute an essential 
step in the efflux of phospholipids and cholesterol to apoA-I. However, ABCA1 does not 
interact with the main forms of HDL that are present in plasma: it shows no interaction 
with HDL2 (larger, less dense particles) and minimal interaction with HDL3 (smaller, 
more dense particles). 
ABCA1 is tightly regulated both transcriptionally and posttranscriptionally to 
maintain intracellular lipid homeostasis. In cholesterol-loaded cells, the oxysterol-
activated nuclear receptor liver X receptor (LXR), in partnership with retinoid X receptor 
(RXR), targets the ABCA1 promoter, leading to increased ABCA1 gene expression and 
enhanced cholesterol efflux from foam cells, similarly, ABCA1 is induced by synthetic 
LXR agonists [243, 244]. Interestingly, the expression of the LXRs is modulated on the 
transcriptional level by agonists of peroxisome proliferators-activated receptor (PPAR) 
[245, 246]. Both systemic and selective hepatic overexpression of ABCA1 in mice results 
in an increase of HDL plasma levels [247, 248]. Conversely, apoA-I and HDL plasma 
levels are dramatically reduced in mice with a liver-specific deletion of ABCA1 [249]. 
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By contrast, the selective inactivation or expression of ABCA1 in macrophages had little 
or no effect on the plasma concentration of HDL [250]. Therefore, hepatic ABCA1 
expression plays an essential role in plasma HDL production and the maintenance of 
HDL levels in plasma. Macrophage ABCA1, although not contributing significantly to 
the maintenance of plasma HDL levels, is a crucial  factor in the prevention of excessive 
cholesterol accumulation in macrophages of the arterial wall and their transformation in 
foam cells [250-252]. 
 
1.8.2  ABCG1-mediated cholesterol efflux 
The human ABCG1 gene has been mapped to chromosome 21q22.3. It is 
composed of 23 exons and has multiple transcripts. Two major transcripts were described 
to encode proteins with alternative amino-termini [253]. ABCG1 is a half-transporter, 
which forms homodimers and is highly expressed in macrophages. Like ABCA1, 
ABCG1 mRNA levels are highly increased when macrophages are either incubated with 
LXR agonists or converted to cholesterol ester-loaded foam cells [254]. Activation of 
PPARγ also induces the expression of ABCG1 [174]. In contrast to ABCA1, ABCG1 
mediates the transport of cholesterol from cells only to the major HDL factions HDL2 and 
HDL3 but not to lipid-free apoA-I [254, 255]. Although the mechanism of action of 
ABCG1 is poorly understood, it seems that ABCG1 redistributes cholesterol to cell 
surface domains where it becomes accessible for removal by HDL [256].  
 
1.9  OBJECTIVES OF THE PROJECT  
The objectives of this project are: 
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1. To investigate the effect of SAA on PPARγ activation  
2. To investigate the mRNA and protein expression level of PPARγ target genes 
after SAA stimulation  
3. To investigate the underlying mechanisms of SAA induced PPARγ activation 
(involvement of MAPK and NF-ĸB pathway)  
4. To examine the effect of SAA on promoting cholesterol efflux  
5. To examine the membrane receptors involved in SAA induced effects 
6. To identify the functional domains of SAA responsible for cholesterol efflux, 
receptor binding and PPARγ activation  
 
The findings from this study would provide insights on the effects of SAA in 
atherosclerosis development and hopefully lead to development of novel therapies to 
































2.1    MATERIALS  
Recombinant synthetic human apolipoprotein SAA was purchased from 
PeproTech (Rocky Hill, NJ, USA). SAA is a hybrid molecule corresponding to human 
SAA1α except for the N-terminal methionine and substitution of asparagine for aspartic 
acid as position 60 and arginine for histidine at position 71. The latter two substituted 
residues are present in SAA2β. The SAA protein was expressed in Escherichia coli, and 
following folding and purification by ion exchange chromatography, the lyophilized 
proteins or aliquots were stored at -80°C until used for cell stimulation. According to the 
supplier, the amount of endotoxin contaminant is less or equal to 0.1 ng/1 µl protein. 
Limulus amebocyte lysate (LAL) assay kit was purchased from Lonza (Walkerswille, 
USA).  [3H] Cholesterol was purchased from PerkinElmer (Waltham, MA, USA). 2-
hexyl-1-cyclopentanone thiosemicarbazone (BLT-1) was purchased from ChemBridge 
(San Diego, CA, USA). Pertussis toxin (PTX), lipopolysaccharide (LPS), 2-(2-Amino-3-
methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), (E)-3-(4-Methylphenylsulfonyl)-2-
propenenitrile (BAY 11-7082), cycloheximide (CHX), mouse anti-β-actin antibody, 
mouse anti-ABCG1 antibody and anti-mouse secondary antibody coupled to horseradish 
peroxidase were from Sigma-Aldrich (St Louis, MO, USA). Lipofectamine 2000 reagent, 
Opti-MEM medium and fetal bovine serum (FBS) were purchased from Invitrogen 
(Carlsbad, CA, USA). Penicillin and Streptomycin was purchased from Gibco. Human 
HDL, apoA-I and polymyxin B (PMB) were obtained from Calbiochem (San Diego, CA, 
USA). 2-Chloro-5-nitro-N-4-pyridinyl-benzamide (T0070907), N-[2-(Cyclohexyloxy)-4-
nitrophenyl]methanesulfonamide (NS-398), 4-(4-Fluorophenyl)-2-(4-
methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), 1,9-Pyrazoloanthrone, 
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Anthrapyrazolone (SP600125), cisglitazone, mouse anti-COX-2 antibody, and NF-кB 
(p50) Transcription Factor Assay Kit were purchased from Cayman Chemical (Ann 
Arbor, MI, USA). Mouse anti ERK1/2 antibody, anti-phospho-ERK 1/2 
(Thy202/Tyr204) antibody, mouse anti-phospho-p38 MAPK (Thr180/Thr182) and mouse 
anti-phospho-JNK (Thr183/Thr185) antibody were from Cell Signaling Technology 
(Beverly, MA, USA). Mouse anti-ABCA1 antibody was from Millipore (Billerica, MA, 
USA). Mouse anti-LXRα antibody and anti-PPARγ were from Abcam (Cambridge, MA, 
USA). Mouse anti-IкB antibody was from R&D Systems (Minneapolis, MN, USA).  
Anti-mouse TLR2 and anti-mouse TLR4 antibodies were from eBioscience (San Diego, 
CA, USA). CignalTM PPAR Reporter Assay Kit was from SABiosciences (Frederick, 
MD, USA). RNeasy Mini Kit, Gel Extraction kit and Midipreparation kit were purchased 
from Qiagen (Hilden, Germany). The LightCycler RNA Master SYBR Green I kit and 
Mini proteinase inhibitor cocktail tablet were obtained from Roche (Penzberg, Germany). 
Nuclear Extract Kit and TransAM PPARγ kit were purchase from Active Motif (Carlsbad, 
CA, USA). Biotin 3’-End DNA Labeling Kit, light shift chemiluminesencent EMSA kit, 
Chemiluminescent Nucleic Acid Detection Module, SuperSignal West Pico 
Chemiluminescent Substrate, Biodyne precut nylon membranes, and Clear Blue X-ray 
film were purchased from Pierce (Rockford, IL, USA). 30% acrylamide and bis-
acrylamide solution and Bradford protein assay reagent was purchased from Bio-Rad 
Laboratories (Hercules, CA, USA). Plasma membrane protein extraction kit was from 
BioVision (Mountain view, CA, USA). THP-1 was purchased from ATCC. HCAEC cell 
line and EGM-2MV Bulletkit were obtained from clonetics. BCA protein Assay Kit was 
purchased from Pierce. The primers, synthetic peptides, WKYMVM, MMK-1, HFYLPM, 
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F-peptide, and WRW4 were synthesized by 1st Base (Singapore). The 96-well white 
plates used for luciferase activity assay were obtained from NUNC (Denmark). SAA 
enzyme-linked immunosorbent assay (ELISA) kit was from Biosource (Belgium). The 
vector pcDNA™3.1(+), One-step RT-PCR Kit, Dual-Luciferase Reporter Gene Assay 
system were obtained from Promega (Madison, WI, USA). BigDyeTM Terminator Cycle 
Sequencing Ready Reaction kit was from Applied Biosystems. 
 
2.2  ROUTINE CELL LINE MAINTENANCE 
2.2.1  Cells lines 
Cell lines used in this project were listed in Table 3.  
Table 3 Cell lines used in this study 
 
Name Details Source 
HepG2 Hepatocellular carcinoma cells Lab stock ATCC No. HB-8065 
THP-1 Human acute monocytic leukemia cell line Lab stock ATCC No. TIB-202 
HCAEC Human Coronary Artery Endothelial Cells Lab stock Lonza No. CC-2585 
 
2.2.2  Cells culture media 
Culture medium for HepG2: 
Dulbecco's Modified Eagle Medium (DMEM) 
10% (v/v) fetal bovine serum (FBS) 
2 mM L-glutamine 
100 units/ml penicillin/streptomycin 
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Culture medium for THP-1: 
RPMI-1640 
10% (v/v) fetal bovine serum (FBS) 
2 mM L-glutamine 
100 units/ml penicillin/streptomycin 
0.05 mM β-mercaptoethanol  
1 mM sodium pyruvate 
10 mM HEPES 
 
Culture medium for HCAEC: 
Endothelial cell basal medium-2 (EGM-2) 
5% (v/v) fetal bovine serum (FBS) 
GA-1000 (Gentamicin, Amphotericin-B)  
Growth supplements: hEGF, hydrocortisone, VEGF, hFGF-B, R3-IGF-1, ascorbic acid 
 
Freezing media: 
90% (v/v) FBS 
10% (v/v) Dimethyl sulfoxide (DMSO) 
 
2.2.3  General cells culture procedures 
Culture procedures for HepG2 and HCAEC: 
In setting up a culture, an appropriate amount of medium (1 ml/5 cm2) was added 
to the tissue-culture grade flasks (Nunc) and equilibrated in a 37°C humidified incubator 
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(Thermo Forma, Marietta, OH) with 5% CO2 for at least 30 minutes. The cryovial 
containing cells was incubated in a 37°C water bath until the frozen contents were almost 
fully thawed and then added drop-wise to 10 ml of culture media in a class II biological 
safety cabinet (Gelman). Cells were centrifuged at 1,000 rpm for 5 minutes to remove the 
freezing buffer containing DMSO. Cells were resuspended with medium and seeded into 
the culture flasks at a concentration of 2,500-5,000 cells/ cm2. After overnight incubation, 
cells were attached to the wall and started to grow. The culture medium was changed to 
remove the cell debris. Subsequently, the cells were cultured with a change of medium 
every other day. Upon obtaining 90% confluence, the cells were detached from the 
surface by 0.025% trypsin-ethylenediaminetetraacetic acid (EDTA) and split at a 1-to-4 
ratio into tissue culture flasks. Briefly, a culture flask was washed twice with 1x PBS and 
added with appropriate amount of 0.025% trypsin (1 ml/25 cm2). The trypsinization was 
continued for 5 minutes at 37°C. After gentle rapping, cells were detached and 10 ml of 
full-supplemented medium was added to neutralize the trysin. Cells were transferred to a 
15 ml tube and centrifuged at 1000 rpm for 5 min to obtain a cell pellet. After removing 
the supernatant, cells were resuspended with the appropriate volume of medium to obtain 
a concentration of between 0.5-2 x 106 cells/ml and plated out on new tissue-culture 
dishes/flasks. 
These cells lines were frozen via the standard slow cooling protocol. Briefly, 
cultures were centrifuged at 1,000 rpm for 5 minutes after trypsinization and 
neutralization. The pellet was then resuspended in freezing media and split into cryovials 
(Nalgene; 1 ml per vial). The vials were placed into a Mr. Frosty freezing aid (Nalgene) 
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and incubated at -80°C overnight. The next day, the vials were transferred to a liquid 
nitrogen tank. 
Culture procedures for THP-1: 
In setting up a culture, an appropriate amount of medium (1 ml/5 cm2) was added 
to the tissue-culture grade flasks (Nunc) and equilibrated in a 37°C humidified incubator 
(Thermo Forma, Marietta, OH, USA) with 5% CO2 for at least 30 minutes. The cryovial 
containing cells was incubated in a 37°C water bath until the frozen contents were almost 
fully thawed and then added drop-wise to 10 ml of culture media in a class II biological 
safety cabinet (Gelman). Cells were plated into the culture flasks at a concentration of 2 x 
105 cells/ cm2. After overnight incubation, cells were centrifuged at 1,000 rpm for 5 
minutes to remove the DMSO and resuspended in 10 ml of fresh media. The cells were 
subcultured when the cell concentration reached 1 x 106 cells/ml and split at a 1-to-4 ratio 
into tissue culture flasks. Cells were transferred to a 15 ml tube and centrifuged at 1000 
rpm for 5 minutes to obtain a cell pellet. After removing the supernatant, cells were 
resuspended with the appropriate volume of medium to obtain a concentration of between 
2 x 105 cells/ml and seeded in new tissue-culture dishes/flasks.  
Cells were seeded at 2 x 106 cells/ml into 35 mm culture wells (2 ml/well) in 
medium supplemented with 50 ng/ml phorbol 12-myristate 13-acetate (Sigma) for 5 days 
to differentiate into macrophage. 
THP-1 cells were frozen via the standard slow cooling protocol. Briefly, cultures 
were centrifuged at 1,000 rpm for 5 minutes. The pellet was then resuspended in freezing 
media and split into cryovials (Nalgene; 1 ml per vial). The vials were placed into a Mr. 
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Frosty freezing aid (Nalgene) and incubated at -80°C overnight. The next day, the vials 
were transferred to a liquid nitrogen tank. 
 
2.3    SAA TREATMENT 
In SAA treatment studies, cells were cultured to confluence in 6-well plates and 
stimulated with 5-40 µg/ml of SAA for 0-24 hours. The normal SAA level is considered 
to be less than 0.1 µM or 1.25 µg/ml. Under inflammatory conditions, the maximal levels 
could be up to 80 µM or 1 mg/ml [257]. The concentrations of SAA (5–40 µg/ml) tested 
were within the range that represented low-grade inflammation, a level which has been 
shown to put an individual at risk of CAD by many clinical studies [124, 258]. In the 
PPARγ receptor study, cells were pretreated with 1 nM of PPARγ antagonist, T0070907 
for 1 hour and then treated with 20 µg/ml of SAA or 5 µM of PPARγ agonist, ciglitazone 
in serum-free medium for 4 and 8 hours. To investigate the effect of possible endotoxin 
contaminants in recombinant protein sample, SAA (20 µg/ml) was either treated with 
polymyxin B (50 µg/ml) for 45 minutes at 37°C in PBS or heated at 100°C for 30 
minutes.       
In the mitogen-activated protein kinases (MAPK) pathway, COX-2 and NF-кB 
pathway study, cells were pretreated with vehicle, 50 µM of ERK1/2 inhibitor, PD98059, 
10 µM of p38 inhibitor, SB203580, 10 µM of JNK inhibitor, SP600125, 10 µM of COX-
2 inhibitor, NS-398 or 10 µM of NF-кB inhibitor, BAY 11-7082 each for 1 hour and then 
treated with 20 µg/ml SAA in serum-free medium for indicated times. In the receptor 
blocking study, cells were pretreated with vehicle, 500 ng/ml of FPRL-1 inhibitor, PTX, 
5 µM of SR-BI inhibitor, BLT-1, 5 mg/ml of anti-TLR2 or anti-TLR4 for 1 hour and then 
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treated with 20 µg/ml of SAA for 4 hours. To determine if ERK1/2 phosphorylation was 
induced by SAA directly or mediated through synthesis of other signaling proteins, 100 
µM of the translation inhibitor, cycloheximide (CHX), was added to the cells for 1 hour 
before SAA treatment. 
 
2.4    MEASUREMENT OF ENDOTOXIN ACTIVITY  
The endotoxin activity of SAA was determined using the Limulus amebocyte 
lysate (LAL) assay kit (Lonza). LAL test is a quantitative test for gram-negative bacterial 
endotoxin. LAL assay was performed according to the manufacturer’s recommendations. 
Briefly, the sterile microplate was pre-equilibrated at 37°C for 10 minutes. 50 µl of 
sample or standard was carefully dispensed into the appropriate microplate well. At time 
T = 0, 50 µl of LAL was added into each well and mixed by tapping the side of the plate 
repeatedly. At T = 10 minutes, 100 µl of pre-warmed substrate solution was added and 
mixed by pipetting up and down. At T = 16 minutes, 100 µl of stop solution (10% sodium 
dodecylsulfate solution) was added to stop the reaction. Te absorbance was read at 405 
nm on a spectrophotometer. The endotoxin concentration was calculated according to the 
manufacturer’s instructions. We found that 10 µg SAA contained 4.1 endotoxin unites 
(EU). 
 
2.5   RNA ISOLATION 
Total RNA was isolated from fresh cells using RNeasy Mini Kit (Qiagen). The 
cells were cultured to confluence and treated with 5-40 µg/ml of SAA for 0-24 hours. At 
the endpoint, cells were washed twice with 1 x PBS and disrupted by addition of Buffer 
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RLT containing 1% (v/v) β-mercaptoethanol. The lysate was homogenized by passing 30 
times through a 1 ml tip. One volume of 70% ethanol was added to the homogenized 
lysate and mixed well by pipetting. The sample was applied to an RNeasy mini column 
and centrifuged for 15 seconds at 13,000 rpm. The flow-through was discarded and the 
column was washed with Buffer RW1. After washing two more times with Buffer RPE, 
the column was centrifuged for 2 minutes at 13,000 rpm to dry the RNeasy silica-gel 
membrane. Finally, 30-50 µl RNase-free water was added directly onto the membrane 
and centrifuged at 13,000 rpm for 1 minute. The concentration of the eluted total RNA 
was quantified by NanoDrop N-1000 UV-Vis Spectrophotometer (Thermo Scientific). 
 
2.6     QUANTITATIVE REAL-TIME PCR (qRT-PCR) 
Quantitative real-time PCR was used to investigate the gene expression profile. 
To obtain enough statistical power, each group had at least 3 individual samples. The 
LightCycler RNA Master SYBR Green I kits (Roche) were used to quantify the starting 
mRNA of the selected genes. This kit uses a hot-start reverse transcription-PCR protocol 
to provide very sensitive detection and quantification of defined RNA sequences. The 
house-keeping gene glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as 
an internal control. Following the manufacturer’s instructions, 90 ng of RNA template, 
primers, Mn(OAc)2, and LightCycler RNA Master SYBR Green I were mixed well and 
transferred into LightCycler capillaries. The LightCycler 2.0 system program was set up 
to conduct reverse transcription, denaturation, amplification, melting curve analysis, and 
final cooling. The temperature and duration of each procedure was set up as 
recommended by the manufacturer’s manual.  
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The sequences of the primers used were as follows:  
Table 4 Primer sequences for qRT-PCR analysis 
 
GAPDH F 5’- CACTCCACCTTTGACGC -3’ 
R 5’- GGTCCAGGGGTCTTACTCC -3’ 
ABCG1 F 5’- CAGTCGCTCCTTAGCACCA -3’ 
R 5’- TCCATGCTCGGACTCTCTG -3’ 
ABCA1 F 5’- GGAGGCAATGGCACTGAGGAA -3’ 
R 5’- CCTGCCTTG TGGCTGGAGTGT -3’ 
LXRα F 5’- AGCGTCCACTCAGAGCAAG -3’ 
R 5’- ACAGTCATTCGTGCACATCC -3’ 
PPARγ F 5’- TCTGGCCCACCAACTTTGGG -3’ 
R 5’- CTTCACAAGCATGAACTCCA -3’ 
COX-1 F 5’- GCTATTCCGGCCCCAACT -3’ 
R 5’- GATGAAGGTGGCATTGACAAACT -3’ 
COX-2 F 5’- ACTGTACGGGGTTTGTGACTGG -3’ 
R 5’- GAAAGGGCATTAATTAGAATGGGAACG -3’ 
SAA1 F 5’- CTGCAGAAGTGATCAGCG -3’ 
R 5’- ATTGTGTACCCTCTCCCC -3’ 
SAA2 F 5’- CTGCAGAAGTGATCAGCA -3’ 
R 5’- ATTATATGCCATATCTCAGC -3’ 
SR-BI F 5’- ACCGCACCTTCCAGTTCCAG -3’ 
R 5’- ATCACCGCCGCACCCAAG -3’ 
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The qRT-PCR conditions were: 
Reverse transcription   61°C   20 min 
Denaturation   95°C   1 min 
Denaturation    95°C  5 sec  
Annealing   55°C  10 sec    45 cycles 
Extension    72°C  13 sec  
The crossing point of each sample was measured and the relative treatment versus 
control ratio of each target gene was analyzd with LightCycler Software Version 3.5. A 
gene-specific mRNA was normalized to GAPDH mRNA. The expression of each mRNA 
was determined using the 2-ΔCT threshold cycle method [257]. 
 
2.7   PROTEIN EXTRACTION 
The stimulated and unstimulated cells in 6-well plate were washed with ice-cold 1 
x PBS. The cells were lysed with 1 x cell lysis buffer (62.5 mM Tris-HCL, pH 6.8, 2% 
w/v SDS, 10% glycerol and 50 mM DTT, proteinase inhibitor cocktail). After 
homogenizing by repeated passing through a 27-gauge needle, detergent insoluble 
materials were pelleted by centrifugation for 10 minutes at 12,000 rpm at 4°C. The 
soluble supernatant fraction was transferred to a new tube. Total protein concentrations 
were determined by BCA protein Assay Kit (Pierce) according to the manufacturer’s 
instruction with BSA as standard. Protein samples were stored at -80°C. 
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2.8   MEMBRANE PROTEIN EXTRACTION 
Membrane proteins were extracted by plasma membrane protein extraction kit 
(BioVision). The stimulated and unstimulated cells in 6-well plate were scraped in 1x 
PBS and harvested by centrifugation at 3000 rpm for 5 minutes. Cells were washed with 
1 ml of ice cold 1x PBS before lysis. The cell pellet was homogenized in 1 ml of 
Homogenize Buffer Mix for 30-50 times on ice. The homogenate was transferred to a 1.5 
ml microcentrifuge tube and spinned at 700 g for 10 minutes at 4°C. The resulting pellet 
was the total cellular membrane protein. The protein concentrations were determined by 
BCA protein Assay Kit (Pierce). Membrane protein samples were stored at -80°C. 
 
2.9    SDS-PAGE AND WESTERN BLOT 













Table 5. Compositions of SDS-PAGE 
Component Final concentration 
Separating Gel 
30% Acrylamide: Bis (29:1) 2.25 ml 
1.5 M Tris-Cl pH 8.8 1.125 ml 
10% SDS 45 µl 
10% Ammonium persulphate 45 µl 
TEMED 3.6 µl 
H2O 1.035 ml 
Stacking Gel 
30% Acrylamide: Bis (29:1) 265 µl 
1.0 M Tris-Cl pH 6.8 187.5 µl 
10% SDS 15 µl 
10% Ammonium persulphate 15 µl 
TEMED 1.5 µl 
H2O 1.013 ml 
 
Thirty-microgram of protein samples were loaded and separated via 10-15% SDS-
PAGE. After an electrotransfer for 2 hours at 100 V, the nitrocellulose membranes were 
blocked for 1 hour in blocking buffer (5% non-fat milk, 25 mM Tris, 137 mM NaCl, 3 
mM KCl, 0.1% Tween-20, 0.05% sodium azide, pH 7.4,). After blocking, the membranes 
were washed with TTBS buffer (25 mM Tris, 137 mM NaCl, 3 mM KCl, 0.1% Tween-
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20, 0.05% sodium azide, pH 7.6) for three times, 10 minutes each. The membrane was 
then placed in primary antibodies diluted in 5 ml blocking buffer for 1 hour at room 
temperature or overnight at 4°C. After washing, the membrane was incubated with 
diluted secondary antibody for 1 hour at room temperature. The blots were developed 
with SuperSignal West Pico Chemiluminescent substrate (Pierce) for 5 minute and 
exposed with Clear Blue X-ray film (Pierce). Anti-ABCA1 antibody (Millipore), anti-
ABCG1 antibody (Sigma-Aldrich), anti-LXRα antibody (Abcam), anti-PPARγ antibody 
(Abcam), anti-IкB antibody (R&D systems), anti-COX-2 antibody (Cayman Chemical), 
anti-ERK1/2 antibody (Cell Signaling) and anti-phospho-ERK 1/2 (Thy202/Tyr204) 
(Cell Signaling) antibody were used at a concentration of 1:1000. Anti-β-actin antibody 
(Sigma-Aldrich) was used at a concentration of 1:5000. Anti-rabbit secondary antibody 
(Cell Signaling) and anti-mouse secondary antibody (Thermo Scientific) coupled to 
horseradish peroxidase were used at a concentration of 1:10000.  
 
2.10    NUCLEAR PROTEIN EXTRACTION 
 Nuclear protein was isolated using the Nuclear Extract Kit. Briefly, HepG2 cells 
(1 x 106 cells) were incubated with 20 µg/ml of SAA for different times as indicated. 
Cells were washed twice with 5 ml of ice-cold PBS/Phosphatase Inhibitor Solution (1 x 
PBS, 20 mM NaF, 1 mM β-glycerophosphate, 1 mM Na3OV4) and centrifuged at 300 x g 
for 5 minutes at 4°C to harvest the cells. Cell pellet was resuspended in 300 µl of ice-cold 
Hypotonic Buffer (20 mM Hepes, pH 7.5, 5 mM NaF, 10 µM Na2MoO4, 0.1 mM EDTA) 
and incubated on ice for 15 minutes to allow cells to swell. Then 30 µl of 10% Nonidet P-
40 was added into the cells and followed by 30 seconds centrifugation at 4°C in a 
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microcentrifuge (Beckman). The pellet was resuspended in 30 µl of ice-cold extraction 
buffer (10 mM Hepes, pH 7.9, 0.1 mM EDTA, 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM 
DTT, 0.5 mM PMSF, 1 µg/ml Pepstatin A, 1 µg/ml Leupeptin, 10 µg/ml Aprotinin, 20 
mM NaF, 1 mM β-glycerophosphate, 10 mM Na3OV4, 25% glycerol) and vortexed for 15 
seconds at highest setting. The tubes were rocked gently on ice for 30 minutes on a 
shaking platform (Stuart Scientific). Finally, the samples were centrifuged at 14,000 x g 
for 10 minutes at 4°C. The supernatant (nuclear fraction) was transferred into a pre-
chilled microfuge tube and stored at -80°C in aliquots. One small aliquot of nuclear 
extract was used to quantitate the protein concentration. 
 
2.11   CHOLESTEROL EFFLUX ASSAY 
Cells were seeded on six-well plates at a density of 5 × 105 cells/well. After 
incubation for  24 hours, the cells were labeled with 1 µCi/ml [3H]cholesterol 
(PerkinElmer) for 24 hours in medium containing 10% FBS. The cells were washed five 
times with PBS containing 1 mg/ml BSA and equilibrated in serum-free medium 
containing 0.2% fatty acid-free BSA for 16 hours. HepG2 cells labeled with [3H] 
cholesterol were preincubated with SAA (20 µg/ml) or H2O as a control for 4 hours. 
Following incubation, the cells were washed extensively with PBS to remove all 
radioactivity in the preincubation medium. Thereafter, cells were incubated for 1-24 
hours at 37 °C in media with or without lipoproteins or lipid free apolipoproteins (HDL, 
40 µg/ml; apoA-I, 10 µg/ml). Following incubation, the medium was collected, and cells 
were washed three times with PBS containing 1 mg/ml fatty acid-free BSA. Radioactivity 
in the medium was measured directly in a liquid scintillation counter. Cells were lysed 
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with 0.1 N NaOH and 0.1% SDS for 30 minutes at room temperature and counted for 
radioactivity. Efflux was calculated as the percentage of counts in the medium to the 
counts in the medium and cells together. 
 
2.12   PPARγ ACTIVITY ASSAY 
PPARγ transcription factor activity was assayed using an enzyme-linked 
immunosorbent assay-based kit to detect and confirm activation of the PPARγ 
transcription factor (Active Motif, Carlsbad, CA, USA). HepG2 cells were seeded on the 
six-well plate in the serum-free medium for 24 hours and treated with SAA (20 µg/ml) or 
one of the following controls: LPS (4 ng/ml and 100 ng/ml), heat-treated LPS and SAA 
(100 °C, 30 minutes), LPS and SAA treated with polymyxin B (50 µg/ml, 1 hour), and 
apoA-I (20 µg/ml) for 4 hours. The cells were then rinsed, and nuclear protein was 
extracted as described in 2.10. Nuclear extracts were added to a 96-well plate containing 
immobilized oligonucleotides bearing peroxisome proliferators-response elements (5’-
AACTAGGTC AAAGGTCA-3’). After 1 hour, the wells were incubated with diluted 
primary PPARγ antibody to detect the accessible epitope on PPARγ protein upon DNA 
binding. The horseradish peroxidase-conjugated secondary antibody was added and 
incubated for 1 hour at room temperature. The reaction was stopped with stopping 






2.13   ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
HepG2 cells were seeded on the six-well plate in the serum-free medium for 24 
hours and treated with SAA (20 µg/ml) for 4 hours. Nuclear extracts were prepared with 
a Nuclear Extraction Kit (Active Motif, Carlsbad, CA, USA). The double-stranded 
oligonucleotide probe containing the PPRE motif (5’-CAAAACTAGGTCAAAGGTCA-
3’) was labeled with biotin using the Biotin 3’-End DNA Labeling Kit (Pierce, Rockford, 
IL, USA). Labeling reaction mixture consisting of 25 µl of ultrapure water, 10 µl of 5x 
TdT reaction buffer, 5 pmol of probe, 5 µl of 5 µM Biotin-11-dUTP and 5 µl of  2 U/µl 
TdT (terminal deoxynucleotidyl transferase) was added in a 0.2 ml PCR tube and the 
reaction was incubated at 37°C for 30 minutes. 2.5 µl of 0.2 M EDTA was added into the 
tube to stop the reaction. 50 µl of chloroform:isoamyl alcohol (24:1) was added into each 
reaction to extract the TdT. The aqueous phase was kept for EMSA assay. The probes 
were annealed by mixing equal amounts of labeled complementary oligos, denatured at 
90°C for 1 minute, and slowly cooled and incubated at 48°C (melting temperature) for 30 
minutes. 
  PPARγ binding activity was determined using the light shift chemiluminesencent 
EMSA kit (Pierce). The nucleoprotein binding reaction was performed via combination 
of 5 µg of nuclear extract and labeled probe for 30 minutes in all reactions at room 
temperature in the presence or absence of a 200-fold excess of unlabeled specific PPRE 
probe or unlabeled mutated PPRE probe (5’-CAAAACTAGCACAAAGCACA-3’). For 
the supershift experiment, extracts were preincubated with 2 µg of monoclonal anti-
PPARγ (Active Motif) for 30 minutes before the labeled probe was added. Protein/DNA 
mixtures were separated on 6% non-denaturing polyacrylamide gels in 0.5x TBE (45 mM 
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Tris-HCl, 45 mM Boric acid, 1 mM EDTA, pH 8.3) at 100 V. Proteins and bound probes 
were transferred to a positively charged nylon membrane (Pierce) in 0.5x TBE at 380 mA 
for 1 hour. The transferred DNA was cross-linked to the membrane with UV stratalinker 
1800 (Stratagene). The biotin-labeled DNA was detected with a Chemiluminescent 
Nucleic Acid Detection Module (Pierce), developed and exposed with Clear Blue X-ray 
film (Pierce). 
For NF-кB EMSA assay, the double-stranded consensus oligonucleotides used in 
this study was: 5’-AGTTGAGGGGACTTTCCCAGGGC-3’. The unlabeled mutated 
probe was: 5’-AGTTGAGGCGACTTTCCCAGGC-3’. 
 
2.14    TRANSFECTION AND LUCIFERASE ASSAY 
 The PPRE-luc reporter and Renilla luciferase construct were purchased from 
SABiosciences. The PPRE-luc construct encodes the firefly luciferase reporter gene 
under the control of a minimal (m) CMV promoter and tandem repeats of the PPAR 
transcriptional response element. This construct monitors both increases and decreases in 
the transcriptional activity of PPAR. The constitutively expressing Renilla construct 
encodes the Renilla luciferase reporter gene under the control of a CMV immmediatly 
early enhancer/promoter and acts as an internal control for normalizing transfection 
efficiencies and monitoring cell viability. PPARγ cDNAs were cloned into mammalian 
expression vector pcDNA3.1 between KpnI and XhoI restriction sites. To measure the 
PPARγ activity, HepG2 cells (1.25 × 105 cells/well) were transfected with PPRE-luc or 
Renilla luciferase construct and pcDNA3.1- PPARγ using Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacturer’s protocol. After transfection for 48 hours, the 
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cells were stimulated by SAA (20 µg/ml) or H2O for 4 hours, lysed and subjected to 
luciferase assays using a Dual-Luciferase Reporter Gene Assay system (Promega) 
according to the manufacturer’s instructions. Serum-free medium was used for the 
treatment of HepG2 cells with SAA (20 µg/ml). 
For luciferase activity assays, a Dual-Luciferase Reporter Gene Assay system 
(Promega) was used. Briefly, the medium was removed, cells were rinsed with 1x PBS 
and lysed by incubation for 15 minutes at room temperature with 1x Passive Lysis 
Buffer. Aliquots of 20 µl of cell lysate were transferred to white opaque 96-well plate 
(Nunc) prior to addition of 100 µl of Luciferase Assay Buffer II. Firefly luciferase 
activity was determined by an automatic luminometer (Wallac 1420 VICTOR2 multilabel 
counter, PerkinElmer life sciences). Renilla luciferase activity was measured by the same 
machine after dispensing 100 µl of Stop & Glo Reagent. Triplicate wells were prepared 
for each condition and each experiment was repeated at least three times. 
 
2.15   EIA FOR 15d-PGJ2 
The 96-well based EIA kit of 15d-PGJ2 was purchased from Cayman Chemical. 
Cells cultured in six-well plates were pretreated with one of the following experimental 
controls: 50 µM PD98059, 10 µM COX-2 inhibitor, NS-398 or vehicle for 1 hour. The 
cells were then treated with 20 µg/ml of SAA for 2 hours. The cells were then 
homogenized in assay buffer by repeated passing through a 27-gauge needle. An aliquot 
of the cell lysate was used for protein determination. Briefly, the kit uses a polyclonal 
antibody against 15d-PGJ2 to bind, in a competitive manner, the prostaglandin in the 
sample or an alkaline phosphatase molecule that has 15d-PGJ2 covalently attached to it. 
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After a simultaneous incubation, the excess reagents were washed away and p-
nitrophenyl phosphate substrate was added. After a short incubation time, the enzyme 
reaction was stopped and the yellow color generated was evaluated on a microplate 
reader at 405 nm. The concentration of intracellular 15d-PGJ2 was determined by the EIA 
kit according to the manufacturer’s instructions. 
 
2.16    NF-кB (p50) TRANSCRIPTION FACTOR ASSAY 
The nuclear NF-кB level was measured by NF-кB (p50) Transcription Factor 
Assay Kit. This assay combines the principal of the electrophoretic mobility shift assay 
(EMSA) and ELISA. Briefly, 10 µg nuclear extract was incubated for 1 hour in the wells 
pre-coated with a specific double stranded DNA (dsDNA) sequence containing the NF-
кB response elements. After washing, the sample wells were incubated with specific 
primary antibody against NF-кB (human p50) for 1 hour. The sample wells were washed 
again and HRP-conjugated secondary antibody was added and incubated for another 1 
hour at room temperature. After a thorough washing, the samples wells were incubated 
with 100 µl of developing solution for 15-45 minutes. When the positive control sample 
turned into dark blue color, 100 µl of stop solution was added into each well. The 
absorbance was read at OD 450 nm in a spectrophotometric plate reader (Spectra Plus, 
TECAN).  
 
2.17    SAA-HDL ASSOCIATION 
To study the effect of lipid-associated SAA, high density lipoprotein (HDL)-
associated SAA was prepared in medium via addition of various concentrations of HDL 
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to SAA (20 µg/ml) before incubation at room temperature for 15 minutes with shaking. 
The medium was then incubated at 37 °C for 15 minutes before treatment. 
 
2.18    siRNA-MEDIATED GENE SILENCING 
Scrambled control RNA oligonucleotides and siRNA to SAA1, SAA2, ABCA1, 
ABCG1 and SR-BI obtained from Dharmacon were used to suppress their expression in 
HepG2 cells. The transfection of siRNA was performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. Briefly, HepG2 cells grown in 
6-well plates were transfected with 100 pmol of siRNA using Lipofectamine 2000 in 
Opti-MEM medium (Invitrogen). After 4 hours incubation, the medium was changed to 
complete DMEM medium. The cells were incubated for a further 44 hours, washed and 
stimulated with 20 µg/ml of SAA for 4 hours. The cells were harvested for RNA 
extraction, nuclear extraction, quantitative real-time PCR, cholesterol efflux assay and 
PPARγ transcriptional activity assay.  










Table 6. siRNA sequences for gene silencing. 







































2.19 BACTERIAL WORK 
2.19.1 Media 
Luria Broth (LB) containing10 g of tryptone, 5 g of NaCl and 5 g of yeast extract 
in 1 liter sterile water was used for all bacteria culture in this project. LB agar plate was 
used for initial bacteria growth. 100 µg/ml of ampicillin was used for selection of bacteria 
carrying transformed vectors whenever necessary. 
 
2.19.2  Competent cell preparation 
DH5α supE44 AlacU169 (p80 lacZ AM15) hsdR17 recA1 endA1 gyrA96 thi-1 
relA1 E.coli cells (NEB) were streaked onto LB agar plates and cultured overnight at 
37°C. A single colony was then picked and inoculated into 50 ml LB media and 
incubated at 300 rpm, 37°C until the OD600 value reached 0.6. The cultures were 
harvested via centrifugation at 4000 g for 5 minutes at 4°C. The resultant pellet was 
resuspended in 30 ml of cold 0.1 M MgCl2 (Sigma) and centrifuged again at 4000 g for 5 
minutes at 4°C. With the supernatant discarded, the pellet was resuspended in 20 ml of 
0.1 M CaCl2 (Sigma) and kept on ice for 30 minutes. The cells were collected via 
centrifugation at 4000 g for 5 minutes at 4°C, resuspended in 2 ml of cold 0.1 M 
CaCl2/15% glycerol (Sigma) and aliquoted to 100 µl/tube to be stored at -80°C. These 
bacteria were then ready for transformation. 
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2.19.3 Isolation of plasmid DNA from E.coli 
2.19.3.1  Small scale preparation of plasmid DNA 
Small scale extraction of plasmid DNA was performed following a standard 
miniprep protocol. Briefly, a 1.5 ml overnight culture of E.coli was transferred to a 1.7 ml 
eppendorf tube and the medium was removed by spinning the cells at maximum speed 
(13,300 rpm) for 1 minute in a microfuge (Sorvall Legend micro 17 centrifuge, Thermo 
Scientific). The supernatant was discarded and the pellet was resuspended in 100 µl of 
ice-cold solution I (25 mM Tris, pH 8.0, 10 mM EDTA, pH 8.0, 50 mM glucose) by 
vigorous vortex. 200 µl of freshly prepared solution II (0.2 M NaOH, 0.1% SDS) was 
then added and the tube was immediately inverted 5 times to mix. Following 2 minutes of 
incubation on ice, 150 µl of cold solution III (3.0 M potassium acetate, 0.5 M acetic acid, 
pH 4.8) was added and the tube was then vortexed briefly to mix again. After 5 minutes 
incubation on ice, the tube was centrifuged at 13,300 rpm for 5 minutes and the 
supernatant was transferred to a new tube. 0.9 ml of 100% ethanol was then added to 
precipitate the DNA and the mixture was vortexed shortly. After 5 minutes of incubation 
at room temperature, the tube was centrifuged at the same speed for 5 minutes. The 
supernantant was removed carefully and the pellet was rinsed with 1 ml of 70% ethanol. 
The tube was centrifuged again and the supernatant was discarded. The DNA pellet was 
air-dried and dissolved in 25 µl of TE buffer with 20 µg/ml of RNase (Promega). The 
samples were stored at -20°C for further analysis. 
 
2.19.3.2   Large scale preparation of plasmid DNA 
Large scale extraction of plasmid DNA was carried out using the QIAGEN midi- 
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preparation kit (Hilden, Germany). An overnight 3 ml of E.coli culture was refreshed in 
100 ml of LB containing respective selection antibiotic, ampicillin (Amp). The cells were 
grown at 37°C with vigorous shaking at 200 rpm for 8 hours. The cells were harvested by 
centrifugation at 6,500 rpm in Beckman JA-14 rotor for 15 minutes at 4°C. The medium 
was discarded and 4 ml of buffer P1 was added to lyse the cells. Another 4 ml of buffer 
P2 was added and mixed gently by inverting it several times. After 5 minutes incubation 
at room temperature, 3 ml of chilled buffer P3 was added and the tube was inverted 
several times again. Following 15 minutes incubation on ice, the tube was then 
centrifuged at 13,000 rpm for 30 minutes at 4°C. The supernatant was removed promptly 
and subjected to another round of centrifugation. The supernatant was transferred to 
another tube promptly. At the same time, a QIAGEN-tip 100 was equilibrated with 4 ml 
of buffer QBT and the column was emptied by gravity flow. The supernatant obtained 
earlier was added into the column and was emptied by gravity flow. The QIAGEN-tip 
100 was washed twice with 10 ml of buffer QC. The DNA was eluted with buffer QF. 
The DNA collected was precipitated with 3.5 ml of isopropanol. After 15 minutes 
incubation at room temperature, the tube was centrifuged at 13,000 rpm for 30 minutes at 
4°C. The supernatant was discarded and the resulting pellet was washed with 1.5 ml of 
70% ethanol and centrifuged again at 13,000 rpm for 20 minutes at 4°C. The pellet was 
air-dried and dissolved in 100 µl TE buffer, pH 8.0 containing RNase. The resulting 






2.20.1 Cloning of SAA1 in the pcDNA™3.1(+) vector 
2.20.1.1   Reverse transcriptase-PCR and purification 
Total RNA from the cells was extracted using RNeasy MiniKit (QIAGEN) 
according to the manufacturer’s protocol, and concentrations were determined 
spectrophotometrically at λ260. 100 ng of RNA was used as the template for RT-PCR 
using a One-step RT-PCR Kit (Promega). The primers used were SAA1F: 5’-
CAGGTACCATGAAGCTTCTC-3’ and SAA1R: 5’- GGCAACTCGAGTCAGTATTTC 
TC-3’. 4.3 µl of ddH2O, 4 µl of 5x AMV buffer, 0.4 µl of 10 mM dNTPs mixture, 1 µl of 
both primers (10 µM), 2.5 µl  of 25 mM MgSO4 and 4 µl of template RNA (100 ng) were 
mixed together in a 200 µl PCR tube. 0.4 µl of AMV reverse transcriptase (2 units) and 
0.4 µl of Tfl polymerase (2 units) were added to the mixture finally to make up a 50 µl 
reaction. The reaction conditions were as follows: 
Reverse transcription 45ºC 45 min 
Initial denaturation 94ºC 2 min 
Denaturation  94ºC 30 sec 
Annealing  55ºC 45 sec    35 cycles 
Extension  68ºC 45 sec    
Final extension 68ºC 7 min 
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After subjecting to gel electrophoresis to ensure the correct size, SAA1 RT-PCR 
products were precipitated on ice using 100% ethanol for 30 minutes. It was then spun 
down at 14,000 rpm for 15 minutes. The PCR product pellet was washed with 70% 
ethanol and dissolved in 50 µl of TE buffer, pH 8.0. 
 
2.20.1.2   Digestion 
Restriction enzyme digestion was performed using restriction enzymes from New 
England Biolabs (NEB). The RT-PCR products and the vector pcDNA™3.1(+) were 
digested with XhoI and KpnI at 37°C for three hours. The digestion reaction mixture 
consisting of 0.5 µl (10-20 units) of each enzyme, 3 µl of 10x buffer, 0.3 µl of 100x BSA, 
1-2 µg of RT-PCR products or pcDNA™3.1(+) and nuclease-free water was incubated at 








Figure 8. Map of pcDNA™3.1(+). This figure summarizes the feature of 





2.20.1.3   Gel purification 
The digested products were purified using kit from QIAGEN. The digested 
products were first separated on 1% agarose gel and the DNA bands whose size 
corresponding to the digested plasmid and RT-PCR products were cut from the gel. The 
agarose slices were weighted to the nearest 10 mg and buffer QG was added (3 volumes 
of buffer QG to 1 volume of gel). The agarose gel slices were then incubated at 65°C for 
10 minutes until the gel slices were completely dissolved in buffer QG. After incubation, 
the tubes were centrifuged briefly to collect the sample at the bottom of the tube and 1 gel 
volume of isopropanol was added to the sample. A QIAquick column was placed in a 
collection tube and the respective samples were loaded into each column. The tubes were 
incubated for 1 minute at room temperature and the samples were centrifuged at 14,000 
rpm for 1 minute after incubation. The flow-through was discarded and the column was 
washed with 750 µl of buffer PE. The tubes were centrifuged at 14,000 rpm for 1 minute 
and the collection tubes were replaced with new 1.5 ml eppendorf tubes. 50 µl of EB 
buffer (10 mM Tris-Cl, pH 8.5) was added directly to the top of the glass fiber matrix in 
the column. After incubating the samples for 1 minute at room temperature, the tubes 
were centrifuged at 14,000 rpm for 1 minute to elute DNA sample. 
 
2.20.1.4   Ligation 
The vector pcDNA™3.1(+) was ligated with SAA1 using T4 DNA ligase (NEB) 
based on the molar ratio of 3:1 (insert:vector) in a 20µl of reaction mixture. Ligation was 
performed at room temperature for 2 hours. 
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2.20.1.5   Transformation 
20 µl of DNA ligation mixture was added to 100 µl of competent DH5α bacteria 
and incubated on ice for 30 minutes. Heat shock was applied at 42°C for 2 minutes, and 
the bacteria were placed on ice again for 2 minutes. Recovery was performed by adding 
900 µl of LB and the sample was incubated at 37°C with vigorous shaking for 1 hour. 
The cell pellet was collected via centrifugation, and resuspended in 100 µl of LB media 
and plated out onto LB amp+ plates. The plates were then incubated overnight at 37°C 
and colonies were picked, inoculated and expanded in LB media with 100 µg/ml of 
ampicillin. Plasmid DNA was prepared from transformed E.coli cell pellets as described 
in 2.19.3. 
2.20.1.6   Selection and DNA sequencing 
Plasmids obtained by small-scale preparation were first digested for 2 hours at 
37°C with XhoI and KpnI to check for the plasmid with insert. The plasmid was then 
served as the template for DNA sequencing. BigDyeTM Terminator Cycle Sequencing 
Ready Reaction kit (Applied Biosystem from Perkin-Elmer Corp., Foster, CA, USA) was 
used. Sequencing reaction mixture consisting of 8 µl of Terminator Ready Reaction mix, 
(~1 µg) of DNA template, 1 µl of 50 µM appropriate primer (forward & reverse primer 
respectively) and 10 µl of deionized water was added in a 0.2 ml PCR tube and a thermal 
cycling was carried out according to the following program: 25 cycles of denaturation at 
96 °C for 30 seconds, annealing of primer at 50°C for 15 seconds and extension at 60°C 
for 4 minutes. To precipitate the extended DNA, the extension reaction was incubated 
with 2.0 µl of 3 M sodium acetate and 50 µl of 95% ethanol at room temperature for 20 
minutes. It was then centrifuged at 14,000 rpm for 30 minutes. The supernatant was then 
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carefully aspirated and the pellet was rinsed with 250 µl of 70% ethanol followed by 
centrifugation at 14,000 rpm for 5 minutes. The air-dried sample was dissolved in 12 µl 
of Hi-Di Formamide and analyzed in ABI PRISM®3100 Genetic Analyzer (Applied 
Biosystems Inc, USA). 
 
2.20.2 Other subclonings 
2.20.2.1 Generation of pcDNA3.1-SAA1-NLS 
The cloning procedures were almost the same as described above. The plasmid 
pcDNA3.1-SAA1-NLS was constructed by inserting a 318 bp XhoI to KpnI fragment 
carrying the SAA1cDNA sequence without the first 18-amino acid signal peptide into 
pcDNA3.1 vector.  
 
2.20.2.2 Generation of pcDNA3.1-SAA1-G8D 
A 369 bp XhoI to KpnI fragment carrying the SAA1 cDNA sequence with a single 
nucleotide GàA substitution at codon 8 was inserted into pcDNA3.1 vector, which 
resulted in a single amino acid substitution, altering codon 8 from a glycine (GGC) to an 
aspartic acid (GAC). 
 
2.20.2.3 Generation of pcDNA3.1-SAA1Δ1-11 
A 336 bp XhoI to KpnI fragment carrying the truncated SAA1 cDNA sequence 
with a deletion of codons from 1 to 11 was inserted into pcDNA3.1 vector, which 
resulted in a deletion of the wild-type sequence +1RSFFSFLGEAF+11.  
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2.20.2.4 Generation of pcDNA3.1-PPARγ 
A 1.4 kb XhoI to KpnI fragment carrying the human PPARγ cDNA sequence was 
inserted into pcDNA3.1 vector. 
 
2.21   PLASMID DNA TRANSFECTION  
Cells were seeded at 8 x 105 cells/well into 6-well plate (2 ml/well) and 
transfected using lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. Briefly, 10 µl of lipofectamine 2000 and 4 µl of DNA were diluted in 250 µl 
of Opti-MEM medium (Invitrogen) separately. After 5 minutes incubation at room 
temperature, the diluted DNA was combined with the diluted lipofectamine 2000 and 
incubated for 20 minutes at room temperature. 500 µl of complexes was added into each 
well and mixed gently by rocking the plate back and forth. After 4 hours incubation under 
standard incubator conditions, the medium was replaced with 2 ml of fresh medium 
supplemented with 10% fetal bovine serum (FBS) and the cells were further incubated 
for an additional 68 hours under the same conditions, resulting in a total transfection time 
of 72 hours. The cells were harvested and processed for Western blot analysis and ELISA 
assay. 
 
2.22    DETECTION OF SAA SECRETION 
After culturing transfected cell for 3 days, medium was collected and cells were 
incubated with lysis buffer [62.5 mM Tris-HCl buffer pH 6.8, 2% sodium dodecyl 
sulphate (SDS), 10% glycerol, 50 mM dithiothreitol (DTT)] for 30 minutes. Then cell 
lysates and medium were assayed for human SAA protein using SAA enzyme-linked 
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immunosorbent assay (ELISA) kit (Biosource).The assay was performed according to the 
manufacturer’s instruction and absorbance of samples were read at 450 nm using 
spectrophotometer (Spectra Plus, TECAN). SAA concentration was determined using 
standard curve obtained from protein standards provided by the kit. 
 
2.23    STATISTICAL ANALYSIS 
Measurements were expressed as mean ± standard deviation (SD) from at least 
three samples. For comparison of two samples, data were analyzed using a 2-tailed 
Student’s t-test and statistically significant differences were reported when P<0.05. For 
multiple comparisons, data were analyzed by ANOVA. Statistically significance of 
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3.1 SAA ACTIVATES PPARγ THROUGH EXTRACELLULAR-REGULATED 
KINASE 1/2 AND COX-2 EXPRESSION  
3.1.1 SAA induces PPARγ and expression of its target genes in HepG2 cells  
The expression levels of PPARγ and its target genes LXRα, ABCG1 and ABCA1 
in HepG2 were examined in relation to varying concentrations and times of exposure to 
SAA stimulation. The transcript levels for these four genes were all induced after 
stimulation for 4 hours by SAA in a concentration-dependent manner (Fig. 9a). The 
effect of SAA on the mRNA levels of PPARγ and LXRα was very transient. We could 
only detect a mild increase for both after stimulation for 4 hours. The increases in mRNA 
levels for ABCG1 and ABCA1 were more pronounced than those for PPARγ and LXRα. 
For ABCG1, the effect of SAA stimulation remained for up to 24 hours (Fig. 9b), the 
maximum time point in this study. Western blot analysis confirmed the induction of 
ABCG1, ABCA1 and LXRα protein levels by stimulation with 20 µg/ml of SAA over 
































































Figure 9. SAA induces PPARγ, LXRα, ABCA1 and ABCG1 gene expression in 
HepG2 cells. HepG2 cells were treated with 5-40 µg/ml of SAA for 4 hours (a) and 20 
µg/ml of SAA for indicated times (b). Total RNA was extracted and real-time 
quantitative RT-PCR was performed to determine mRNA expression levels of each gene. 
The mRNA levels of each gene were standardized for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) levels. The results from at least 3 separately performed 
experiments are expressed relative to the controls and presented as the mean fold change 
± SD. (c) HepG2 cells were incubated with 20 µg/ml of SAA for the indicated times. 





Time (h)     0    4    8   24 
PPARγ 
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PPARγ and anti-β-actin antibodies. **P<0.05 vs 0 µg/ml SAA treatment for all the 
genes. *P<0.05 vs 0 group. n=3 to 4.  
 
 
3.1.2 SAA facilitates cholesterol efflux in HepG2 cells 
The ability of SAA to facilitate cholesterol efflux was examined using purified 
lipid-free SAA. The results shown in Figure 9 indicated that when HepG2 cells labeled 
with [3H]cholesterol were preincubated with SAA (20 µg/ml), no significant changes in 
the amount of efflux of cholesterol into the medium without HDL or apoA-I acceptor 
were observed. However, the amount of cholesterol efflux was significantly increased in 
the presence of HDL (Fig. 10a). This increase was more drastic when apoA-I (10 µg/ml) 






































































Figure 10. SAA facilitates cholesterol efflux in HepG2 cells. HepG2 cells were labeled 
with 1 µCi/ml [3H] cholesterol for 24 h, equilibrated in medium in the absence of 
cholesterol for 16 h. The cells were then preincubated with 20 µg/ml of SAA or distilled 
water for 4 h. After this incubation, the cells were washed with 1x PBS for four times. 
The cells were then incubated with medium consisted of DMEM/BSA alone  (null) or  
the same medium  containing  40 µg/ml of HDL (HDL) (a) or 10 µg/ml of apoA-I (apoA-
I) (b) at 37 °C for different periods for the determination of cellular efflux. Medium was 
collected at the indicated time points and assayed for [3H] cholesterol. Cells were lysed 
with 0.1% SDS and 0.1 M NaOH lysis buffer, and radioactivity was determined by 
scintillation counter. The average values are represented (± SD) as the percentage of the 
radioactivity in medium relative to the total radioactivity in cells and medium. * P<0.05 
vs HDL or apoA-I. n=4 to 5. 
 
 
To clarify the roles of ABCA1 and ABCG1 on SAA-induced cholesterol efflux, 
we next examined the effect of acute suppression of ABCA1 or/and ABCG1 on 
cholesterol efflux using synthetic interfering RNA (siRNA) targeting human ABCA1 and 
ABCG1, respectively. As shown in Figure 11a, siRNAs specific to ABCA1 and ABCG1 
efficiently reduced ABCA1 protein levels by ~ 50%. Knockdown of ABCA1 or ABCG1 
expression reduced SAA-induced cholesterol efflux to HDL and apoA-I in HepG2 cells 
(Fig. 11b and 11c). The cholesterol efflux to HDL and apoA-I were more severely 
impaired in ABCA1 and ABCG1 double-knockdown HepG2 cells. Together, these data 
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Figure 11. SAA-facilitated cholesterol efflux in HepG2 cells was mediated by 
ABCA1 and ABCG1. (a) HepG2 cells were transfected with control (scrambled siRNA), 
ABCA1 siRNA or ABCG1 siRNA for two days, and then incubated with SAA (20 
µg/ml) for 4 h. Protein samples were immunoblotted with anti-ABCG1, anti-ABCA1 and 
anti-β-actin antibodies. (b) HepG2 cells were transfected with scrambled siRNA, ABCA1 
siRNA or ABCG1 siRNA for 24 h. HepG2 cells were labeled with 1 µCi/ml [3H] 
cholesterol for another 24 h, equilibrated in medium in the absence of cholesterol for 16 
h. The cells were then preincubated with 20 µg/ml of SAA or distilled water for 4 h. 
After this incubation, the cells were washed with 1x PBS for four times. The cells were 
then incubated with medium consisted of DMEM/BSA alone  (control) or  the same 
medium  containing  10 µg/ml of apoA-I (apoA-I) (b) or 40 µg/ml of HDL (HDL) (c) at 
37 °C for 24 h. Cholesterol efflux was measured as described before. The results from at 
least 4 separately performed experiments are presented as the mean ± SD. * P<0.05 vs 
control group. # P<0.05 vs SAA group. n=4 to 5. 
 
3.1.3 SAA enhances PPARγ activity in HepG2  
As both ABCA1 and ABCG1 are downstream target genes of PPARγ, we 
performed electrophoretic mobility shift assay (EMSA) to investigate the effect of SAA 
on PPARγ binding activity. As shown in Figure 12a, SAA increased PPRE DNA binding 
activity in HepG2 cells. The sequence specificity of SAA-induced PPRE binding was 
demonstrated by inhibition of binding with an excess of unlabeled PPRE probe, while the 
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binding was not affected by the same molar excess of oligonucleotide with a mutated 
PPRE motif. The identity of the PPAR-oligonecleotide complex was verified by a 
supershift assay. To further examine the effect of SAA on PPARγ activity, HepG2 cells 
were co-transfected with a luciferase reporter construct containing PPRE (PPRE-luc) and 
a PPARγ expression vector. With the dual-luciferase assay system, the PPAR Reporter 
(luc) can easily and rapidly monitor PPARγ transcriptional activity in cells. As shown in 
Figure 12b, SAA increased luciferase activity in a concentration-dependent manner. 
We also examined the PPARγ activity in HepG2 cells using an enzyme-linked 
immunosorbent assay-based PPARγ transcription factor activity assay kit. As shown in 
Figure 12c, 5 µM PPARγ agonist, ciglitazone, increased the PPARγ transcriptional 
activity almost by eight-fold compared to the control. SAA (20 µg/ml) also increased 
PPARγ transcriptional activity by more than three-fold, although the effect was milder 
than that of ciglitazone. 
The effect of PPARγ antagonist T0070907 on SAA-induced PPARγ activation 
was examined via the pretreatment of HepG2 cells with of T0070907 (1 nM), for one 
hour. The treated cells were then stimulated with SAA (20 µg/ml) and ciglitazone (5 
µM).  The enhanced PPARγ transcription activity stimulated by SAA and ciglitazone was 
significantly inhibited by T0070907 (Fig. 12c).  
We next investigated whether the PPARγ activation was a direct effect of SAA or 
resulted from contaminating lipopolysaccharide (LPS) in the SAA preparation. The LPS 
content in the recombinant SAA was 0.1 ng/µg of protein or less, translating into 4 ng/ml 
LPS or less in 40 µg/ml of SAA. LPS at this concentration and at a higher concentration 
of 100 ng/ml that we had tested was unable to induce PPARγ activation (Fig. 12d). Given 
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that most proteins are heat-labile while LPS is heat-resistant, we examined the ability of 
heat-treated SAA (20 µg/ml) and LPS (100 ng/ml) to induce PPARγ activation. As 
shown in Figure 10d, SAA could no longer induce PPARγ activation after being heated at 
100 °C for 30 minutes. LPS had no effect on transcription activation with or without heat 
treatment. In parallel experiments, polymyxin B (PMB), an amphiphilic cyclic 
polycationic peptide that specifically binds to LPS and neutralizes its effect, had a 
minimal effect on the potency of SAA-induced PPARγ activation. These results indicate 
that the trace amount of LPS in the SAA preparation did not contribute to the PPARγ 
activation. In another control experiment, apoA-I was used in the PPARγ activation 
assay. Like SAA, apoA-I is another major apolipoprotein of HDL, and they share similar 
structure (amphipathic helices) and function (lipid transport). As shown in Figure 11d, 
apoA-I has no effect on PPARγ transcriptional activity. The gene expression levels of 
ABCG1 and ABCA1 after SAA stimulation for eight hours, as well as PPARγ and  
LXRα after SAA stimulation for four hours, were also inhibited by the PPARγ  
antagonist, T0070907 (Fig. 12e).  
 
                               (a) 
     1      2      3     4     5     6 
PPARγ 
PPARγ supershift 
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Figure 12. SAA enhances PPARγ activation and SAA-induced PPARγ target genes 
expressions are inhibited by PPARγ antagonist. (a) HepG2 cells were stimulated with 
20 µg/ml of SAA for 4 hours and nuclear extracts were prepared. EMSA assay was 
performed using biotin-labeled PPRE probe. Unlabeled PPRE sequence of its mutant 
were added as specific or non-specific competitors as indicated. Lane 1, control; 2, SAA 
treatment; 3, SAA + unlabeled probe; 4, SAA + unlabeled mutant probe; 5, free probe; 6, 
SAA + anti-PPARγ. (b) HepG2 cells were transfected with PPARγ expression vector plus 
PPRE-luc reporter constructs. PPRE-luc reporter activity was measured with a Dual-
Luciferase Reporter Gene Assay system after incubation of transfected cell cultures with 
different doses of SAA for 4 hours. (c) HepG2 cells were pretreated with 1 nM of 
T0070907 or vehicle for 1 hour and then treated with 20 µg/ml of SAA or 5 µM of 
ciglitazone for 4 hours. PPARγ transcriptional activity was determined by a PPARγ 
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transcription factor activity assay kit. (d) HepG2 cells were incubated with LPS (4 ng/ml 
and 100 ng/ml), SAA (20 µg/ml), heat-treated LPS and SAA (100°C for 30 minutes), 
polymyxin B (50 µg/ml, 1 hour)-treated SAA and LPS and apoA-I (20 µg/ml) for 4 hours 
and followed by the PPARγ transcriptional activity assay. (e) Real-time quantitative RT-
PCR was performed to determine mRNA expression levels of each gene, standardizing 
with GAPDH levels. The mRNA levels for PPARγ and LXRα were determined 4 hours 
after SAA (20 µg/ml) stimulation while the mRNA levels for ABCA1 and ABCG1 were 
measured 8 hours after treatment. The results from at least 3 separately performed 
experiments are expressed relative to the controls and presented as the mean fold change 
± SD. * P<0.05 vs 0 or control group. #P<0.05 vs SAA group. n=3 to 5. 
 
3.1.4 SAA-induced PPARγ activation is suppressed by HDL 
Although SAA is largely associated with HDL in circulation, it has been 
speculated that it is available in lipid-free/lipid-poor forms at the site of atherosclerotic 
lesion formation. Therefore, functional differences between lipid-associated and lipid-
free SAA are of great interest. The effects of HDL on SAA-induced PPARγ activation 
was examined by incubating a constant concentration of SAA with varying 
concentrations of HDL. The addition of increasing concentrations of HDL caused a dose-
dependent suppression of SAA-induced PPARγ activation while HDL alone had no effect 
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Figure 13. SAA-induced PPARγ activity is suppressed in the presence of HDL. 
HepG2 cells were incubated with media containing 20 µg/ml of SAA and increasing 
concentrations of HDL (25-100 µg/ml) (SAA+HDL) or media containing HDL only 
(control+HDL) for 4 hours. PPARγ transcription activity was determined by a PPARγ 
transcription factor activity assay kit as previously described. The results from at least 3 
separately performed experiments are expressed relative to the controls and presented as 
the mean fold change ± SD. n= 3 to 5. 
 
 
3.1.5 De novo protein synthesis is required for the SAA-induced PPARγ activation 
Cycloheximide (CHX) is a protein biosynthesis inhibitor. In this study, we 
examined whether de novo protein synthesis is required for the SAA-induced PPARγ 
activation. In a time-course experiment, SAA was shown to increase PPARγ activity 
between 2 and16 hours. The SAA effect on PPARγ subsided after 8 hours. As shown in 
Fig. 14a, the increased PPARγ activity was generally suppressed by CHX, indicating 
endogenous expressed SAA or intermediate molecule(s) involved in SAA-induced 
PPARγ activation. However, CHX could not completely abolish the PPARγ activation 
induced by SAA.  
Acute-phase SAA is synthesized mainly in liver. As such, it is necessary to 
establish whether the observed PPARγ activation could be due to the endogenously 
produced SAA protein. With siRNA gene silencing of SAA1 and SAA2, quantitative RT-
PCR demonstrated 50-60% of mRNA knockdown (Fig. 14b). As shown in Fig. 14c, SAA 
treatment increased PPARγ activation, which was reduced by the knockdown of SAA1, 
suggesting that endogenously expressed SAA1 might also play a role in SAA-induced 
PPARγ activation. PPARγ activity was not affected by SAA2 knockdown. 


























































































































































Figure 14. De novo protein synthesis is required for the SAA-induced PPARγ 
activation. (a) Cells were incubated with 100 µM cycloheximide (CHX) for 1 hour 
before SAA (20 µg/ml) treatment for indicated times. PPARγ transcription activity was 
determined as described before. (b) HepG2 cells were treated with 100 pmol of siRNA to 
SAA1 or SAA2 or scrambled siRNA (control). RNA was extracted and the mRNA levels 
for SAA1 and SAA2 were measured by real-time RT-PCR. (c) PPARγ transcription 
activity was determined as described before.The results from at least 3 separately 
performed experiments are expressed relative to the controls and presented as the mean ± 
SD. *P<0.05 vs 0 or control group. #P<0.05 vs SAA group. n=3 to 5. 
 
 
3.1.6 SAA-induced PPARγ activation and cholesterol efflux in HepG2 are partially 
mediated by SR-BI 
We also assessed the contribution of scavenger receptor class B type I (SR-BI) in 
SAA-induced PPARγ activation and cholesterol efflux by using siRNA against SR-BI. 
Examination of SR-BI level by quantitative RT-PCR demonstrated 60% mRNA 
knockdown (data not shown). As shown in Figure 15, siRNA-mediated SR-BI gene 
silencing partially inhibited PPARγ activation and cholesterol efflux induced by SAA 
treatment. However, siRNA could not completely block the SAA effects, which indicated 
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Figure 15. SAA-induced PPARγ activation and cholesterol efflux in HepG2 is 
partially mediated by SR-BI. HepG2 cells were treated with 100 pmol of siRNA to SR-
BI or scrambled siRNA for 48 hours before SAA (20 µg/ml) treatment for 4 hours. (a) 
PPARγ transcription activity and (b) cholesterol efflux were determined as described 
before. * P<0.05 vs Control. #P<0.05 vs SAA group. n=3. 
 
 
3.1.7 SAA elevates the intracellular 15d-PGJ2 level 
As PPARγ can be activated by a number of intracellular fatty acids such as 15d-
PGJ2 [136, 139, 257], we examined the effect of SAA on the intracellular 15d-PGJ2 level 
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in HepG2 cells using an enzyme immunoassay. As shown in Figure 16, SAA increased 




























Figure 16. SAA induces intracellular 15d-PGJ2 in HepG2. HepG2 cells were 
incubated with 20 µg/ml of SAA for 4 hours, and then the cells were lysed with lysis 
buffer. The concentrations of 15d-PGJ2 were determined by EIA. The results from 3 
separately performed experiments are presented as the mean ± SD. * P<0.05 vs control 
group. n=3. 
 
3.1.8 SAA induces COX-2 expression 
As the 15d-PGJ2 level could be induced by COX expression [258, 259], we next 
examined whether COX expression could be induced by SAA stimulation. SAA 
treatment had no effect on the expression of COX-1 mRNA (Fig. 17a). On the other 
hand, after treatment of HepG2 cells with 20 µg/ml SAA for 4 hours, both the mRNA 
level and the protein level of COX-2 were increased and remained so for up to 24 hours 
as revealed by real-time RT-PCR and Western blot analysis, respectively (Fig. 17b and 
17c).  
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Figure 17. SAA induces COX-2 gene expression in HepG2 cells. HepG2 cells were 
treated with 20 µg/ml of SAA for indicated times. Total RNA was extracted and real-time 
quantitative RT-PCR was performed to determine mRNA expression levels of COX-1 (a) 
and COX-2 (b). The mRNA levels of COX-1 and COX-2 were standardized for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. The results from 3 
separately performed experiments are expressed relative to the controls and presented as 
the mean ± SD. (c) HepG2 cells were incubated with 20 µg/ml of SAA for the indicated 
times. Protein samples were immunoblotted with anti-COX-2 and anti-β-actin antibodies. 
* P<0.05 vs 0 group. n=3. 
 
3.1.9 SAA-induced PPARγ activation is mediated by ERK1/2-dependent COX-2 
expression, and protein translation is required 
Recent reports showed that lipid-free SAA can activate MAPK [120, 215, 217], 
which are important signaling molecules that regulate COX-2 expression [260-262]. 
Therefore, we speculated on the involvement of MAPK signals in SAA-induced COX-2 
in HepG2 cells. Our Western blot data have shown that SAA could induce ERK1/2 
phosphorylation. To evaluate if this is the direct effect of SAA or if it occurs through the 
synthesis of signaling proteins, the HepG2 cells were incubated with 100 µM 
cycloheximide (CHX). ERK1/2 phosphorylation could be observed for the first 30 
minutes despite cycloheximide pretreatment and was only suppressed subsequently while 
ERK1/2 protein levels were unchanged by cycloheximide. For cells not pretreated with 
CHX, ERK1/2 phosphorylation could be sustained for up to 6 hours, the maximum 
duration of this experiment (Fig. 18a). These data indicated that the initial 30 minutes of 
phosphorylation might be the direct effect of exogenous SAA that did not require any 
synthesis of endogenous signaling proteins, whereas the later effects were perhaps 
dependent on endogenous protein that may take more time to synthesize. However, 
phosphorylation of p38 and JNK could not be detected in HepG2 cells after SAA 
treatment. We then examined the effect of ERK1/2 specific inhibitor PD98059 on SAA-
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induced COX-2 mRNA expression. As shown in Figure 18b, SAA-induced COX-2 
mRNA expression was blocked by PD98059, which indicated the involvement of 
ERK1/2 in SAA-induced COX-2 expression. In addition, both NS-398 and PD98059 had 
an inhibitory effect on SAA-induced ABCA1 and ABCG1 mRNA expression (Fig. 18c). 
The SAA-induced intracellular 15d-PGJ2 level was also partially suppressed by these two 
inhibitors (Fig. 18d). Furthermore, SAA-enhanced PPARγ activation was also inhibited 
by NS-398 and PD98059 (Fig. 18e). SAA-facilitated cholesterol efflux was inhibited by 
the same COX-2 and ERK1/2 inhibitors (Fig. 18f and 18g). These results suggested that 
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Figure 18. SAA-induced PPAR activation is mediated by ERK1/2-dependent COX-2 
expression. (a) Cells were incubated with or without 100 µM cycloheximide (CHX) for 1 
hour before SAA (20 µg/ml) treatment for indicated time periods. Protein samples were 
immunoblotted with anti-phospho ERK1/2 (p-ERK), and anti-ERK1/2 antibodies. HepG2 
cells were pretreated with 10 µM NS-398 (NS) or 50 µM PD98059 (PD) or vehicle for 1 
hour and then treated with 20 µg/ml of SAA for 4 hours (For ABCA1 and ABCG1 
mRNA quantitation, cells were treated with 20 µg/ml of SAA for 8 hours). mRNA 
expression levels of COX-2 (b) ABCA1 and ABCG1 (c) were quantified as described  
before. (d)The concentrations of 15d-PGJ2 were determined by EIA assay. (e) PPARγ 
transcriptional activities were measured as described before. (f) HDL (40 µg/ml) or (g) 
apoA-I (10 µg/ml) was used as the cholesterol efflux acceptor for the cholesterol efflux 
assay. Cholesterol efflux was also determined as before. The results from at least 3 
separately performed experiments are presented as the mean ± SD.* P<0.05 vs control 
group. #P<0.05 vs SAA group. n=3 to 4. 
 
 
3.1.10 SAA has the same PPARγ activation effects in HCAEC and THP-1 cell lines 
After establishing that SAA could induce PPARγ activation, we further examined 
the effect of SAA on PPARγ in two other cell lines, HCAEC and THP-1, to determine 
whether this effect is cell line specific. As shown in Figure 19, SAA could increase the 
PPARγ activity in both cell lines and PPARγ activation effect was even drastic in THP-1 
cell line. 

























Figure 19. SAA enhances PPARγ activity in HCAEC and THP-1 cell lines. THP-1 
cells were seeded on 6-well plate at a density of 2 x 106/well and differentiation was 
induced with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) for 5 days. HCAEC (2 x 
106/well) and THP-1 cells were treated with 20 µg/ml of SAA for 4 hours and nuclear 
protein was extracted. PPARγ transcription activity was determined by a PPARγ 
transcription factor activity assay kit. The results from 3 separately performed 
experiments are expressed relative to the controls and presented as the mean fold change 
± SD. * P<0.05 vs control group. n=3. 
 
3.2 SAA ACTIVATES PPARγ THROUGH NF-кB ACTIVATION 
3.2.1 SAA stimulates NF-кB activity 
To investigate the effect of SAA on NF-кB activity in hepatocytes, we used an 
enzyme-linked immunosorbent assay-based NF-кB (p50) transcription factor activity 
assay kit. HepG2 cells were stimulated with 20 µg/ml of SAA for various lengths of time. 
As shown in Figure 20a, SAA stimulated NF-кB (p50) transcriptional activity by almost 
two-fold 30 to 60 minutes after stimulation. NF-кB (p50) transcriptional activity returned 
to basal level 120 minutes after stimulation by SAA, which indicates that SAA has a 
transient effect on NF-кB activation.  
As lipopolysaccharide (LPS) had also been reported to be able to activate NF-кB, 
we next investigated whether the NF-кB activation was a direct effect of SAA or resulted 
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from contaminating LPS in the SAA preparation. The LPS content in the recombinant 
SAA is less than or equal to 0.1 ng/µg protein, translating into less than or equal to 2 
ng/ml LPS for 20 µg/ml SAA. LPS at this concentration or at a concentration of 20 ng/ml 
was unable to induce significant NF-кB activation (Fig. 20b). Given that most proteins 
are heat-labile while LPS is heat-resistant, we examined the ability of heat-treated SAA 
(20 µg/ml) and LPS (20 ng/ml) to induce NF-кB activation. As shown in Figure 19b, NF-
кB activity was not affected by heating LPS at 100°C for 30 minutes. In contrast, SAA 
could no longer induce NF-кB activation after the same heat treatment. In parallel 
experiments, polymyxin B (PMB), an amphiphilic cyclic polycationic peptide that 
specifically binds to LPS and neutralizes its effect, had a minimal effect on the potency of 
SAA-induced NF-кB activation. These results indicate that the trace amount of LPS in 
the SAA preparation cannot account for the NF-кB activation.  
NF-кB activation has been reported to be associated with IкB phosphorylation 
and subsequent degradation [263, 264], thus, the effect of SAA on IкB degradation was 
also examined. Stimulation of HepG2 with 20 µg/ml of SAA for 30-45 minutes elicited a 
degradation of IкB, thus supporting our observation of NF-кB activation by SAA 
stimulation (Fig. 20c). An electrophoretic mobility shift assay showed that SAA 
stimulated binding activity to a consensus NF-кB site in 30 minutes, which was 
effectively competed with the unlabeled NF-кB probe (Fig. 20d). The binding was not 
affected by the same molar excess of oligonucleotide with mutated sequence. The 
identity of the NF-кB oligonecleotide complex was verified by supershift assay (Fig. 
20d). 
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(d) 
Figure 20. SAA stimulates NF-kB activation. HepG2 cells were stimulated with SAA 
(20 µg/ml) for indicated times. (a) NF-кB activity was examined using an ELISA kit. (b) 
HepG2 cells were incubated with SAA (20 µg/ml), LPS (2 ng/ml and 20 ng/ml), heat-
treated LPS and SAA (100°C for 30 minutes), polymyxin B (50 µg/ml, 1 hour)-treated 
LPS and SAA, and apoA-I (20 µg/ml) for 4 hours and followed by the NF-kB 
transcriptional activity assay.  (c) Protein samples were Immunoblotted with anti-I кB 
antibodies. (d) 30 min after SAA stimulation, EMSA was performed to determine the 
binding activity of NF-kB. The concentration of the unlabeled probes used for 
competition was 200-fold in excess. Lane 1, free probe; 2, control; 3, SAA treatment; 4, 
SAA + unlabeled probe; 5, SAA+unlabeled mutant probe; 6, SAA + anti-NF-кB. The 
results from at least 3 separately performed experiments are expressed relative to the 
controls and presented as the mean ± SD. * P<0.05 vs 0 or control group. #P<0.05 vs 
SAA group. n=3 to 5. 
 
3.2.2 SAA-induced COX-2 expression and PPARγ activation are through NF-кB 
pathway 
Our previous data [265] showed that SAA could activate PPARγ transcriptional 
activity through COX-2 expression. The promoter region of COX-2 contains two putative 
NF-кB binding sites [266].  NF-кB had been shown to be a positive regulator of COX-2 
expression [267, 268]. Our previous data also showed that COX-2 was involved in the 
SAA-induced PPARγ activation through the ERK1/2 pathway. To assess the role of NF-
кB in COX-2 expression and PPARγ activation, we examined the effect of specific 
   1      2    3    4    5    6 
NF-кB 
NF-кB 
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pathway inhibitors on COX-2 expression and PPARγ activation. Our data confirmed that 
SAA stimulation increased the COX-2 expression (Fig. 21a) and that COX-2 inhibitor, 
NS398, could partially suppress SAA-induced PPARγ activation (Fig. 21b). 
Preincubation with NF-кB inhibitor, BAY 11-7082, was shown to significantly inhibit 
SAA-stimulated COX-2 expression and SAA-induced PPARγ activation (Fig. 21a and 
21b), indicating that both SAA-stimulated COX-2 expression and SAA-induced PPARγ 
activation is through NF-кB pathway. In our previous study, we found that SAA could 
increase intracellular 15d-PGJ2, a potent PPARγ ligand, through COX-2 overexpression. 
In this study, the increased intracellular 15d-PGJ2 stimulated by SAA was reduced by 
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Figure 21. SAA-induced COX-2 expression and PPARγ activation is through NF-кB 
pathway. HepG2 cells were pre-incubated with 10 µM of BAY11-7082, 10 µM NS-398 
or vehicle before SAA stimulation (20 µg/ml) for 4 hours. (a) Total RNA was extracted 
and real-time quantitative RT-PCR was performed to determine mRNA expression levels 
of COX-2. The mRNA levels of COX-2 were standardized for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) levels. (b) PPARγ transcription activity was 
determined by a PPARγ transcription factor activity assay kit. (c) 15d-PGJ2 level was 
measured by an EIA kit. The results from at least 3 separately performed experiments are 
expressed relative to the controls and presented as the mean ± SD. *P<0.05 vs control 
group. #P<0.05 vs SAA group. n=3 to 5. 
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3.2.3 SAA-induced PPARγ activation is completely blocked by the combination of 
ERK1/2 and NF-кB inhibitors 
As mentioned in section 3.1.9 that ERK1/2 inhibitor, PD98059, could partially 
suppress the SAA-induced PPARγ activation. Here, we investigated the effect of the 
combination of both ERK1/2 (PD98059) and NF-кB (BAY 11-7082) inhibitors on 
PPARγ activation. While the SAA-induced PPARγ activation was only partially blocked 
by either ERK1/2 or NF-кB inhibitor, the combination of both inhibitors completely 



























Figure 22. SAA-induced PPARγ activation is completely blocked by the combination 
of ERK1/2 and NF-кB inhibitors. Cells were pre-incubated with 10 µM of BAY11-
7082, 50 µM PD98059, 10 µM of BAY11-7082 + 50 µM PD98059 or vehicle before 
SAA stimulation (20 µg/ml) for 4 hours. PPARγ transcription activity  was determined 
by a PPARγ transcription factor activity assay kit. The results from at least 3 separately 
performed experiments are expressed relative to the controls and presented as the mean ± 
SD. * P<0.05 vs Control group. #P<0.05 vs SAA group. n=3 to 5. 
 
3.2.4 SAA-induced NF-кB activation is suppressed by HDL 
Although SAA is largely associated with HDL in circulation, it has been 
speculated that it is available in lipid-free/lipid-poor forms at the site of atherosclerotic 
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lesion formation. Therefore, functional differences between lipid-associated and lipid-
free SAA are of great interest. Studies were performed to determine if HDL-associated 
SAA induces NF-кB activation or if the association with HDL affects these effects by 
incubating a constant concentration of SAA with varying concentrations of HDL. The 
addition of increasing concentrations of HDL caused a dose-dependent suppression in 
SAA-induced NF-кB activation while HDL alone had no effect on NF-кB activation (Fig. 
23). HDL (25 µg/ml) cultured with SAA reduced the SAA-induced response by 14%, and 
suppression reached 33% and 96% with 50 and 100 µg/ml HDL, respectively. Inhibition 
































Figure 23. SAA-induced NF-кB activity is inhibited by HDL association. HepG2 cells 
were incubated with media containing 20 µg/ml of SAA and increasing concentrations of 
HDL (25-100 µg/ml) (SAA-HDL) or media containing HDL only (control-HDL) for 4 
hours. NF-кB activity was determined as described before. The results from at least 3 
separately performed experiments are expressed relative to the controls and presented as 
the mean ± SD. * P<0.05 vs 0 group. n=3 to 5. 
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3.3 SAA-INDUCED EFFECTS ARE MEDIATED BY DIFFERENT 
RECEPTORS 
3.3.1 FPRL-1 and TLR4 are involved in SAA-induced PPARγ and NF-кB   
activation 
As the effects of SAA have been postulated to be initiated by its binding to 
specific membrane receptors, we further examined the involvement of FPRL-1, SR-BI, 
TLR-2 and TLR-4 in SAA-induced effects. PTX is a known inhibitor for FPRL-1. BLT-1 
is a low-molecular weight compound that has known to be an inhibitor of SR-BI selective 
uptake and cholesterol efflux. Specific antibodies against TLR2 and TLR4 were also used 
to examine the involvement of these two receptors in the SAA-induced effects. In this 
study, we found that pretreatment of HepG2 cells with PTX, a known effective FPRL-1 
inhibitor, and anti-TLR4 antibody caused a marked reduction in COX-2 expression (Fig. 
24a). However, BLT-1 and anti-TLR2, which effectively blocks SR-BI and TLR2 
respectively, had no significant effect on SAA-induced COX-2 expression (Fig. 24a). 
Preincubation of HepG2 cells with PTX, anti-TLR2 and anti-TLR4 demonstrated a 
partial inhibitory effect to SAA-induced NF-кB activation (Fig. 24b). Pretreatment of 
HepG2 cells with PTX, anti-TLR2 and anti-TLR4 also showed a similar inhibitory effect 
to SAA-induced PPARγ activation, although to a less extent (Fig. 24c). Our data 
indicated that FPRL-1 and TLR4 are likely to be the receptors through which SAA 
mediates its effects to initiate COX-2 expression, NF-кB and PPARγ activation. TLR2 
apprears to be involved in SAA-induced NF-кB and PPARγ activation. 
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   (c) 
Figure 24. FPRL-1 and TLR4 are involved in SAA-mediated effects. HepG2 cells 
were pretreated with 500 ng/ml of pertussis toxin (PTX), 5 µM of BLT-1, 5 µg/ml of 
anti-TLR2, and 5 µg/ml of anti-TLR4 for 1 hour and then treated with 20 µg/ml of SAA 
for 4 hours. (a) Total RNA was extracted and real-time quantitative RT-PCR was 
performed to determine mRNA expression levels of COX-2. The mRNA levels of COX-
2 were standardized for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. (b) 
NF-кB activity was examined as desribed before. (c) PPARγ transcription activity was 
determined by a PPARγ transcription factor activity assay kit as described before. The 
results from 3 separately performed experiments are expressed relative to the controls and 




3.3.2 SAA-enhanced cholesterol efflux is partially through SR-BI 
We next assessed the contribution of these receptors in SAA-enhanced cholesterol 
efflux. As shown in Figure 25, treatment with BLT-1 could partially inhibit the 
cholesterol efflux to HDL (Fig. 25a) and apoA-I (Fig. 25b), suggesting the involvement 
of SR-BI. However, the efflux levels in both cases were not completely blocked by BLT-
1. Therefore, our data supports the partial involvement of SR-BI in SAA-enhanced 
cholesterol efflux. The SAA-enhanced cholesterol efflux to HDL and apoA-I was also 
slightly suppressed by PTX, anti-TLR2 and anti-TLR4, but the reduction was not 
statistically significant. 
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Figure 25. SAA-enhanced cholesterol efflux is partially through SR-BI. Radiolabeled 
HepG2 cells were pretreated with 500 ng/ml of pertussis toxin (PTX), 5 µM of BLT-1, 5 
µg/ml of anti-TLR2, and 5 µg/ml of anti-TLR4 for 1 hour and then treated with 20 µg/ml 
of SAA for 4 hours. Cholesterol efflux was measured as described before after an efflux 
period of 24 hours with (a) HDL (40 µg/ml) or (b) apoA-I (10 µg/ml). The average 
values are represented (± SD) as the percentage of the radioactivity in medium relative to 
the total radioactivity in cells and medium. The results from at least 3 separately 
performed experiments are expressed relative to the controls and presented as the mean ± 
SD.* P<0.05 vs control group. # P<0.05 vs SAA group. n=3 to 5. 
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3.3.3 NF-кB and PPARγ activation via FPRL-1 is SAA-selective 
The finding that FPRL-1 stimulation by SAA induced NF-кB and PPARγ 
activation led us to examine whether other FPRL-1 agonists also elicit the similar effects. 
Thus, we investigated the effects of several FPRL-1 agonists such as MMK-1 [269], 
WKYMVM [270], HFYLPM [271] and F-peptide (EGSDTITLPCRIKQFINMWQE) 
[272] on NF-кB and PPARγ activation. As shown in Figure 26, none of these FPRL-1 
agonists, except SAA, stimulated NF-кB and PPARγ activation, suggesting that NF-кB 
and PPARγ activation via FPRL-1 is SAA-selective. We also examined the effect of an 
FPRL-1 antagonist, WRW4 (Trp-Arg-Trp-Trp-Trp-Trp) [273]. The pretreatment of 
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Figure 26. NF-кB and PPARγ activation via FPRL-1 is SAA-selective. HepG2 cells 
were stimulated with several FPRL-1 agonists (1 µM WKYMVM, 30 µM F-peptide, 1 
µM MMK-1, 5 µM HFYLPM), and 20 µg/ml SAA or pretreated with 10 µM WRW4 and 
then treated with 20 µg/ml SAA for 4 hours. (a) NF-кB and (b) PPAR activities were 
measured as described before. The results from at least 3 separately performed 
experiments are expressed relative to the controls and presented as the mean ± SD.* 
P<0.05 vs control group. n=3 to 5. 
 
 
3.4 THE N-TERMINAL IS ESSENTIAL FOR SAA PROTEIN EXPRESSION, 
SECRETION AND CHOLESTEROL EFFLUX 
3.4.1 mutSAA protein expression and secretion are impaired in HEK293 cells 
The transfection host Human Embryonic Kidney (HEK) 293 cells secrete very 
low level of SAA, therefore, we chose this cell line to examine the effect of 
endogenously expressed protein and to identify the functional domain and essential 
amino acid of SAA in cholesterol efflux.  Quantitative real-time PCR data showed that 
mRNA of SAA in cells transfected with wild-type and mutant SAA plasmids increased 
significantly compared with cells incubated with transfection reagent and cells 
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transfected with control plasmid (Fig. 27). No large discrepancy was observed in the 































Figure 27. The SAA mRNA levels are similar after transfection with different 
constructs. HEK293 cells were transfected with SAA or mutSAA constructs using 
lipofectamine 2000 for 3 days under standard conditions. mRNA expression levels of 
SAA were quantified as described  before. Control, cells were transfected with empty 
plasmid pcDNA3.1 without SAA sequence; mutSAA (NLS), SAA construct without the 
leading sequence peptide from -18 - -1; mutSAA (G8D), SAA construct with an amino 
acid substitution of Glycine to Aspartic acid at the 8th residue; mutSAA (Δ1— 11), SAA 
construct with the deletion of first 11 amino acids; none, cells were incubated with 
transfection reagent only. Experimental results are expressed as means ± S.D. The results 
from least 3 separately performed experiments are expressed relative to the controls and 
presented as the mean ± SD.* P<0.05 vs control group. n=3. 
 
 
The SAA protein expression in HEK293 cells was determined by measuring SAA 
concentration in the medium of transfected HEK293 cells using ELISA three days after 
transfection. Table 6 shows the expression of SAA protein levels in the medium as well 
as in the cell lysates. Cells transfected with wild-type SAA construct yielded high protein 
expression and approximately 90% of wild-type SAA was secreted to the medium. In 
contrast, the total yield of mutant SAA proteins decreased dramatically. In addition, the 
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majority of mutant proteins were found to be present in the cell lysate. Only 32-48% of 
mutant SAA protein was secreted to the medium, which suggested an essential role of the 
leading peptide (-18 — -1 segment) and the first 11 amino acids, especially the 8th 
residue in the expression and secretion of SAA protein. 
 
Plasmid used for the 
transfection 
SAA concentration in the 
medium (ng/ml) 
SAA concentration in cell 
lysate (ng/ml) 
wild-type SAA 1196.52 ± 152.92 143.12 ± 2.19 
mutSAA (NLS) 50.70 ± 2.58 54.64 ± 8.57 
mutSAA (G8D) 200.39 ± 35.38 429.12 ± 17.59 
mutSAA (Δ1— 11) 220.21 ± 22.77 236.67 ± 12.67 
Control 0 0 
None 0  0 
 
Table 7. ELISA measurement of SAA in transfected HEK293 cells. HEK293 cells 
were transfected with SAA or mutSAA constructs using lipofectamine 2000 for 3 days 
under standard conditions. Cells were lysed in 1 ml of lysis buffer containing 1% Triton 
X-100, 150 mM of NaCl, 50 mM of EDTA and 1x protease inhibitors mixtures.SAA 
concentrations in the medium and cell lysate were determined by ELISA in duplicate 
experiments. None, cells were incubated with transfection reagent only; control, cells 
were transfected with empty plasmid pcDNA3.1 without SAA sequence; mutSAA (NLS), 
SAA construct without the leading sequence peptide from -18 - -1; mutSAA (G8D), SAA 
construct with an amino acid substitution of Glycine to Aspartic acid at the 8th residue; 
mutSAA (Δ1— 11), SAA construct with the deletion of first 11 amino acids. The results 
from 4 separately performed experiments are expressed relative to the controls and 
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3.4.2 Cholesterol efflux is impaired in HEK293 cells transfected with mutSAA 
constructs 
Transfected cells were labeled with [3H]cholesterol one day after transfection. 
The results showed the cholesterol efflux to HDL increased significantly in cells 
expressing wild-type SAA compared to the cholesterol efflux level in cells transfected 
with empty vector and in cells incubated with transfection reagent (Fig. 28). The 
cholesterol efflux to HDL was impaired severely in cells expressing mutant SAA proteins 






































Figure 28. Cholesterol efflux is impaired in HEK293 cells transfected with mutSAA 
constructs. Transfected HEK293 cells were labeled with [3H] cholesterol for 24 hours at 
37°C, equilibrated in medium in the absence of cholesterol for 16 hours. After the 
equilibration, the cells were washed with 1x PBS for four times. The cells were then 
incubated with medium containing 40 µg/ml of HDL at 37 °C for 24 hours. Medium was 
collected and assayed for [3H] cholesterol. Cells were lysed with 0.1% SDS and 0.1 M 
NaOH lysis buffer, and radioactivity was determined by scintillation counter. The 
average values are represented (± SD) as the percentage of the radioactivity in medium 
relative to the total radioactivity in cells and medium. Control, cells were transfected with 
empty plasmid pcDNA3.1 without SAA sequence; wtSAA, cells were transfected with 
pcDNA3.1-wild-type SAA; mutSAA (NLS), cells were transfected with SAA construct 
without the leading sequence peptide from -18 - -1; mutSAA (G8D), cells were 
transfected with SAA construct with an amino acid substitution of Glycine to Aspartic 
acid at the 8th residue; mutSAA (Δ1— 11), cells were transfected with SAA construct 
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with the deletion of first 11 amino acids; none, cells were incubated with transfection 
reagent only. The results from at least 3 separately performed experiments are expressed 
relative to the controls and presented as the mean ± SD.* P<0.05 vs control group. # 
P<0.05 vs SAA group. n=4 to 5. 
 
 
3.4.3 PPARγ activity is impaired in HEK293 cells transfected with mutSAA 
constructs 
 The cells were subjected to PPARγ activity assay 72 hours after transfection. The 
results showed the PPARγ activity increased significantly in cells expressing wild-type 
SAA compared to that in cells transfected with empty vector and in cells incubated with 
transfection reagent only (Fig. 29). The PPARγ activity was impaired severely in cells 































Figure 29. PPARγ activity is impaired in HEK293 cells transfected with mutSAA 
constructs. HEK293 cells were transfected with SAA or mutSAA constructs using 
lipofectamine 2000 for 3 days under standard conditions. Cells were lysed, nuclear 
proteins were extracted and PPARγ activity assay were performed as described 
previously. None, cells were incubated with transfection reagent only; control, cells were 
transfected with empty plasmid pcDNA3.1 without SAA sequence; mutSAA (NLS), 
SAA construct without the leading sequence peptide from -18 - -1; mutSAA (G8D), SAA 
construct with an amino acid substitution of Glycine to Aspartic acid at the 8th residue; 
mutSAA (Δ1— 11), SAA construct with the deletion of first 11 amino acids. The results 
from 4 separately performed experiments are expressed relative to the controls and 
presented as the mean ± SD. 
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SAA is one of the major acute phase plasma proteins involved in multiple 
physiological and pathological processes. As the liver is the major site of SAA synthesis, 
we chose the human hepatocellular carcinoma cell line (HepG2) to conduct the 
experiments. The normal SAA level is considered to be less than 0.1 µM or 1.25 µg/ml. 
Under inflammatory conditions, the maximal levels could be up to 80 µM or 1 mg/ml. 
The concentrations of SAA (5–40 µg/ml) tested were within the range that represented 
low-grade inflammation [257]. Our data have shown that SAA could activate PPARγ 
through the ERK1/2 and NF-кB pathways, leading to upregulation of PPARγ target gene 
expression, such as ABCA1 and ABCG1 (Fig. 30). We also demonstrated that SAA-
induced PPARγ activation is dependent on COX-2.  The finding that preincubation of 
HepG2 with SAA increased cholesterol efflux suggests that SAA may serve to promote 
the efflux of cholesterol from the liver. SAA-induced PPARγ activation has not been 
reported previously in studies involving SAA. Furthermore, the receptors involved in 
SAA-induced effects were also investigated. The effect of SAA on PPARγ activity is 
mediated, at least in part, by FPRL-1, TLR4 and SR-BI receptors. Finally, we found that 
the N-terminal of SAA is essential for SAA protein expression, secretion and PPARγ 
activation. 
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Figure 30. Schematic diagram of the proposed mechanism of cholesterol efflux 
through SAA-induced PPARγ activation of its target genes. 
 
4.1  SAA INDUCES PPARγ ACTIVATION 
 In this study, we found PPARγ transcriptional activity was increased by three-fold 
because of SAA stimulation in HepG2 cells. However, there was no significant 
corresponding change in the PPARγ mRNA levels. The data demonstrated that the 
PPARγ inhibitor T0070907 had a significant inhibitory effect on PPARγ transcription, 
which is consistent with a previous publication [274]. T0070907 covalently binds to 
Cys313 of PPARγ, inducing conformational changes that block the recruitment of 
transcriptional cofactors to the PPARγ-RXR heterodimer. However, further experiments 
should be carried out to elucidate this observation.  We employed three approaches to 
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evaluate the relationship between SAA and PPARγ: ELISA, EMSA and PPRE-luc 
reporter system. Our data showed that SAA strengthened PPRE binding and enhanced 
PPARγ transcriptional activity. The expression levels of PPARγ target genes such as 
ABCA1 and ABCG1 were also increased by SAA treatment.  
The finding that SAA induces PPARγ activation could have relevance to the role 
of SAA in atherogenesis. Some recent studies have suggested that SAA may be 
atheroprotective [126]. Although some other studies have suggested a proatherogenic role 
of SAA signaling, this role may depend on the cell type involved as well as the specific 
receptors and signaling pathways downstream of SAA stimulation. There seems to be 
abundant evidence for a proatherogenic role of SAA signaling in endothelial cells and 
monocytes [116, 217]. In contrast, our data suggest that SAA signaling in hepatocytes 
may have antiatherogenic consequences through PPARγ activation. 
 As SAA-induced PPARγ activation is the key finding of our study, we would like 
to know whether this effect also applies to other cell lines. Both endothelial cells and 
monocytes play important roles in atherosclerosis development, we repeated the PPARγ 
activity assay in a endothelial cell line, human coronary artery endothelial cells 
(HCAEC), and a monocyte cell line, human acute monocytic leukemia cell line, THP-1. 
Both of them showed an enhancement in PPARγ activity after SAA stimulation, though 
the response of THP-1 to SAA treatment was more drastic, indicating that the discovery 
was not a cell-specific effect. 
A recent study reported that porcine recombinant SAA protein reduced the level 
of PPARγ expression by 60% and its target gene (aP2, LPL and ACC1) mRNA levels 
were also decreased in porcine differentiated adipocytes [275]. The discrepancy between 
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their observations and our findings could be due to tissue specific regulation of these 
genes as well as distinct cofactors involved in the transcriptional machinery. Most 
importantly, PPARγ activity was not measured in their study. 
In another study, it was reported that adipocyte hypertrophy induced SAA3 
mRNA expression in murine preadipocytes (3T3-L1) [276]. The researchers found 
PPARγ DNA binding activity to be decreased in hypertrophic adipocytes but without any 
change in PPARγ mRNA levels. However, their study was based on a murine cell line 
and the reported increase in SAA was SAA3 and not SAA1, the acute-phase protein we 
studied. Although the relative map positions and transcriptional orientations provide 
strong evidence that human SAA1 and mouse SAA1 are evolutionary homologs, as are 
human SAA2 and mouse SAA2, comparison of the amino acid sequence alignments of 
SAA isoforms in mice and human demonstrated that mouse SAA3 is most similar to the 
human isoform SAA1. It was speculated that mouse SAA3 might be functionally similar 
to human SAA1 based on the sequence similarity. However, the hypothesis has not been 
confirmed. In addition, human SAA1 is predominantly expressed in liver while mouse 
SAA3 is primarily expressed extrahepatically and most abundant in adipose tissue and 
colon. In their study, the decrease in PPARγ activity and increase in SAA3 were parallel 
observations and the authors did not establish any link between murine SAA3 and 
PPARγ DNA binding activity.  We had established in our paper that SAA1 is able to 
activate PPARγ. SAA was an observed effect in their study after induction of adipocyte 
hypertrophy (the cause), whereas SAA1 was tested as the cause for other effects in our 
study. Furthermore, their effects were detected 6-7 days after hypertrophy induction 
whereas we examined PPARγ activity 4 hours after SAA treatment. 
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The protein biosynthesis inhibitor, CHX, was shown to have an inhibitory effect 
on SAA-induced PPARγ activation, suggesting that another signaling molecule or 
endogenous SAA could play a role in this process. In order to determine whether the 
unknown molecule is a cytokine or endogenously produced SAA, the PPARγ activity 
assay was repeated with siRNA against SAA1 and SAA2. Knockdown of SAA1 could 
partially reduce the PPARγ activation induced by exogenous SAA while siSAA2 did not 
show such effects. The possibility of one or several other signaling molecules being 
involved in this process could not be excluded, and more experiments need to be 
conducted. 
 
4.2  SAA INDUCES THE EXPRESSION OF ABCA1 AND ABCG1, AND 
ENHANCES CHOLESTEROL EFFLUX 
 In this study, we showed that SAA could induce ABCA1 and ABCG1 expression 
in HepG2 cells. Both ABCA1 and ABCG1 play important roles in cholesterol efflux. 
Thus, functional expression of both ABC transporters is critical for preventing 
atherogenesis. It has been reported that SAA induces ABCA1 and ABCG1 in 
macrophages [126]. Both of them are members of the ATP-binding cassette transporter 
family. Our results have shown that SAA-induced ABCA1 and ABCG1 expression is 
mediated by PPARγ activation. Furthurmore, siRNA to ABCA1 and ABCG1 decreased 
the SAA-induced cholesterol efflux. These data suggested that the activation of PPARγ 
might lead to an anti-atherogenic effect through cholesterol efflux.  
 Accumulating evidence has shown that SAA could facilitate cholesterol efflux 
[98, 99, 103, 110]. The data in these studies showed that SAA may enhance cholesterol 
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efflux by functioning as an acceptor and by increasing the availability of cellular free 
cholesterol. We demonstrated through this study that SAA could increase the efflux of 
cholesterol to both HDL and apoA-I. However, the increase in cholesterol efflux was 
more drastic when apoA-I was used as the cholesterol efflux acceptor compared to HDL. 
The possible reason for this observation could be the different acceptor specificity for 
ABCA1 and ABCG1. ABCA1 is a key regulator of the export of cholesterol to lipid-free 
apolipoproteins, forming nascent HDL, but it is unlikely to be involved in the export of 
cholesterol to mature HDL [238]. ABCG1 facilitates the export of cholesterol to HDL but 
not to lipid-free apoA-I [277]. When HDL was used as the efflux acceptor, only the 
overexpressed ABCG1 could facilitate cholesterol efflux. ABCA1 would not be effective 
as HDL is not the appropriate acceptor for ABCA-1-dependent cholesterol efflux, 
although it was upregulated through SAA stimulation. On the other hand, when apoA-I 
was used as an acceptor, ABCA1 could facilitate the efflux of cholesterol to apoA-I to 
form nascent HDL, which in turn could serve as an acceptor for ABCG1-mediated 
cholesterol efflux. Therefore, with the use of apoA-I as the acceptor, both ABCA1 and 
ABCG1 could contribute to the cholesterol efflux while only ABCG1 could contribute to 
the efflux when HDL is used. A recent study suggested that ABCA1 and ABCG1 operate 
in synergy to mediate the efflux of cholesterol to apoA-I [278]. Previous studies have 
shown that SAA could enhance cholesterol efflux either through being a cholesterol 
acceptor [103] or by improving the availability of intracellular cholesterol through 
activation of neutral cholesterol ester hydrolase (nCEH) and deactivation of acyl-CoA 
cholesteryl acyl transferase (ACAT) [98, 99]. ACAT esterifies cholesterol for storage, 
and nCEH de-esterifies cholesterol for transport. By inhibiting ACAT and enhancing 
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nCEH activities, SAA shifts the equilibrium from stored cholesterol ester to transportable 
free cholesterol, thereby promoting cholesterol efflux. Here, we propose that an 
additional mechanism in which SAA could induce cholesterol efflux indirectly through 
upregulation of the efflux mediators ABCA1 and ABCG1 might be in place. This is a 
novel mechanism and our experimental evidence has suggested addition action points of 
SAA in cholesterol efflux. This study showed an important link between inflammatory 
signals and lipid efflux pathways in hepatocytes. It is highly possible that the induction of 
ABCA1 and ABCG1 by SAA facilitates the resolution of inflammatory lesions and 
represents a beneficial role of the hepatocytes in the context of atherosclerosis. 
 
4.3  THE EFFECT OF SAA IS NOT DUE TO BACTERIAL 
CONTAMINATION IN RECOMBINANT SAA PROTEIN 
 The SAA we used is a recombinant protein produced in Escherichia coli. In 
previous studies, bacterial contamination of recombinant proteins has complicated data 
interpretation when evaluating SAA-induced effects. We have taken precautions in the 
determining whether SAA or the contaminating bacterial product, such as LPS, is 
responsible for the PPARγ and NF-кB activation. Although the endotoxin content of 
SAA preparation is negligible (0.1 ng/µg), we examined the possible contribution of LPS 
on the SAA-induced PPARγ and NF-кB activation using polymyxin B, a potent inhibitor 
of LPS. Polymyxin B (PMB) is an amphophilic cyclic polycationic peptide that forms a 
complex with LPS and prevents LPS-induced proinflammatory cytokine production.   
 We concluded that the SAA-induced PPARγ activation was not due to trace 
amounts of endotoxin contaminating the recombinant protein (≤ 4 ng/ml of LPS in 
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culture with 40 µl/ml of SAA) because of the following: 1) LPS at much higher 
concentration (100 ng/ml for PPARγ activity assay and 20 ng/ml for NF-кB activity 
assay) did not significantly induce PPARγ or NF-кB activation after 4 hours stimulation; 
2) heat denaturation destroyed the ability of SAA to induce PPARγ and NF-кB 
activation, whereas heat-treated LPS retained its ability to slightly induce PPARγ and 
NF-кB activation; 3) SAA-induced PPARγ and NF-кB activation was not affected by 
polymyxin B treatment, which specifically binds to LPS and neutralizes its effect. 
 
4.4  LIPID-FREE SAA AND HDL-CONJUGATED SAA HAVE DIFFERENT 
EFFECTS 
In our study, we used a lipid-poor recombinant synthetic human SAA as well as a 
HDL-associated SAA. SAA is known to exist in plasma mainly as a HDL apolipoprotein 
[90]. This raises the question of the physiological relevance of the lipid-poor SAA. 
Although most of the SAA in plasma is associated with lipoproteins, it is possible that 
sufficient SAA may exist in a lipid-free form to exert its physiological function. Evidence 
of the relevance of the lipid-poor SAA comes from the analysis of serum SAA 
distribution during an acute phase reaction induced by LPS injection in mice [279]. In 
this study, 15% of SAA was present in the lipid-poor form. Considering the high levels of 
SAA synthesized during the acute phase response, the physiological functions of the 
lipid-poor SAA demonstrated in various studies could be easily contributed to this 
portion [57, 215, 217].  During the acute phase reaction, the serum concentration of SAA 
may reach 80-1000 µg/ml [53], exhausting the capacity of HDL to bind all of the SAA 
and allowing some of the SAA to be in a lipid-poor form . In addition, there is evidence 
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that suggests that newly synthesized SAA is secreted in a lipid-free form from 
hepatocytes [280]. It is possible that local production of SAA may contribute to its 
accumulation and that the SAA is potentially available to the cells in a free, non-
lipoprotein-bound form to activate PPARγ and enhance cholesterol efflux. 
 The acute phase response is associated with a decline in plasma HDL cholesterol 
and apoprotein A-I [281]. The mechanism responsible for decreased plasma HDL is not 
clearly understood. It was assumed that SAA enrichment of HDL probably is responsible 
for decreased plasma apoA-I and HDL levels because SAA could displace apoA-I from 
HDL and SAA-enriched HDL particles are rapidly cleared from the circulation [282].  
However, this proposal appears unlikely since the drop in plasma HDL during the acute 
phase response occurs rapidly and before SAA accumulation [281]. The prior hypothesis 
of reverse cholesterol transport (RCT) proposes that the majority of plasma HDL 
originates from peripheral tissue and is subsequently transferred to the liver [283]. Recent 
studies have challenged this model based on the finding of reconstitution of ABCA1-
deficient mice with bone marrow from wild-type mice does not result in restoration of 
plasma HDL cholesterol levels, suggesting that monocytes and macrophages may not be 
a significant source of plasma HDL [250]. Furthermore, overexpression of ABCA1 in 
liver raised plasma HDL concentration [284] and plasma HDL concentration in liver-
specific Abca1-knockout mice was 80% lower than those of wild-type mice [249]. These 
findings suggest that liver is the major source of HDL. 
 Our study provided new insight into the observed decrease of HDL and increase 
of SAA during the acute phase. We showed that SAA stimulation to HepG2 cells 
increased the cholesterol efflux to both HDL and apoA-I, which is in accordance with the 
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previous conclusion and liver might be an important organ to contribute to HDL 
generation, especially in the acute phase response. To compensate for the plasma HDL 
decrease during acute phase, the increased plasma SAA concentration might result in 
HDL generation by promoting intracellular cholesterol efflux from hepatocytes. As SAA 
is synthesized mainly in the liver, hepatocytes may be exposed to an even higher 
concentration of SAA and contribute to the HDL generation through PPARγ activation. 
 We also examined the effect of HDL-associated SAA on PPARγ activation. The 
data show that HDL did not alter basal PPARγ activity, but the association with HDL 
inhibits the SAA-induced PPARγ activation. This is consistent with several previous 
studies which demonstrated that HDL inhibited the chemotactic activity of SAA [52] and 
decreased tissue factor and sPLA2 induction [116, 234]. It is possible that HDL either 
competes for receptor binding sites, thereby reducing SAA triggering, or the HDL-SAA 
complex is a less effective activator.  
 Interestingly, although both SAA and apoA-I are mainly associated with HDL in 
blood and apoA-I can be replaced by SAA as the major apolipoprotein in HDL during the 
acute-phase response, apoA-I itself did not induce PPARγ, indicating a unique function 
for SAA. 
 
 4.5  SAA INDUCES COX-2 EXPRESSION AND SUBSEQUENTLY 
INCREASES THE INTRACELLULAR 15d-PGJ2 LEVEL 
 It is well known that 15d-PGJ2, one of the ultimate dehydration products of PGD2, 
is a strong PPARγ activator [136].  Because COXs have the ability to produce 
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prostaglandins, we speculated that SAA may induce endogenous prostaglandin 
production via COXs expression.  
 Cyclooxygenase (COX) is the key and rate-limiting enzyme in the conversion of 
arachidonic acid (AA) to prostaglandins (PGs), which are lipid metabolites that are 
involved in several physiological and pathological processes, including inflammation 
[285]. Two distinct COX isoforms have been characterized, COX-1 and COX-2, that 
differ in terms of regulatory mechanisms, tissue distribution and preferential coupling to 
upstream and downstream enzymes [286-288]. COX-1, which is constitutively expressed 
in most tissues, has been classically considered as the isoform primarily responsible for 
homeostatic PG synthesis [289]. By contrast, COX-2 is mainly induced in response to 
inflammatory stimuli, which led to the concept that selective inhibition of COX-2 can 
reduce inflammation without affecting the physiological functions of COX-1-derived 
PGs.  
 COX-2 catalyzes the conversion of arachidonic acid to PGG2 and further to 
PGH2. PGH2 is subsequently modified into PGD2. The bioactive 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2), which is physiologically formed by dehydration and 
isomerization of the PGD2 [290]. Recent study suggested that intracellular 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2) level could be increased by COX-2 overexpression 
[258, 259]. It has been reported that SAA induces COX-2 expression in monocytes and 
epithelial cells [214, 233]. However, the mechanisms of SAA-induced COX-2 expression 
are not clearly understood. 
 Our results demonstrated that SAA did not induce COX-1 expression but induced 
COX-2 expression, suggesting that SAA-induced COX-2 expression was selective. Some 
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groups also reported that 15d-PGJ2 level could be induced by COX-2 expression [258]. In 
accordance with these results, we found that SAA stimulation increased the intracellular 
15d-PGJ2 level and this induction was probably due to the COX-2 overexpression.  We 
also showed that COX-2 inhibitor, NS398, exerted an inhibitory effect on the SAA-
induced 15d-PGJ2, suggesting the involvement of COX-2. The enhanced PPARγ activity 
by SAA was also partially but significantly inhibited by NS398. These results suggest 
that COX-2-mediated increase in intracellular 15d-PGJ2 level is one of the mechanisms 
by which SAA induces PPARγ activation. 
 The role of COX-2 in atherosclerosis is a controversial issue in the past several 
years. It has been reported that selective COX-2 inhibition suppresses atherosclerotic 
lesion formation in LDL receptor-deficient mice [291], indicating that COX-2 act as an 
inducer of atherosclerosis. Conversly, several recent studies have showed that treatment 
with COX-2 inhibitors in humans does not decrease, but rather increases cardiovascular 
events [292-294]. According to our findings, it is possible that several eicosanoids 
produced by COX-2 may play a protective role in controlling atherosclerotic progression, 
through the activation of PPARγ. 
 
4.6 SAA-INDUCED COX-2 EXPRESSION COULD BE MEDIATED 
THROUGH ERK1/2 AND NF-кB 
 SAA-induced COX-2 expression had been shown in monocytes and endothelial 
cells [233], but the underlying mechanism is not clearly elucidated. MAPKs are 
important signaling molecules that regulate COX-2 expression [260]. Previous study 
showed that PPARγ activation could be mediated by overexpression of COX-2 [295]. 
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Therefore, several pathways which could induce the overexpresion of COX-2 may also 
activate PPARγ. 
 Firstly, our data revealed that SAA induced COX-2 expression in HepG2 cells 
and that this was mediated by ERK1/2 activation. In addition, SAA-induced PPARγ 
activation was inhibited by inhibitors of COX-2 and ERK1/2, suggesting that SAA-
induced PPARγ activation is mediated by ERK1/2-dependent COX-2 expression. 
However, the pattern of SAA-induced ERK1/2 phosphorylation we found in this study 
was slightly different from the some other ERK1/2 activation pattern. In some of the 
studies, the ERK1/2 activation could be detected within 10 minutes after SAA 
stimulation and it usually subsides after 15 minutes [120, 215]. We showed that SAA 
increased the level of phosphorylation of ERK1/2 at 10 minutes, and this effect remained 
up to 6 hours. These data are in line with the results that lipid-free SAA can activate 
MAPKs, especially ERK1/2, from several other studies [120, 215, 217]. We also 
evaluated whether ERK1/2 phosphorylation is the direct effect of SAA or through the 
synthesis of signaling proteins by using the translation inhibitor cycloheximide (CHX).   
ERK1/2 phosphorylation could be observed for the first 30 minutes despite 
cycloheximide pretreatment and was only suppressed subsequently while ERK1/2 protein 
levels were unchanged by cycloheximide. These data indicated that the initial 30 minutes 
of ERK1/2 phosphorylation might be the direct effect of SAA that did not require any 
synthesis of signaling proteins whereas the later effects were perhaps dependent on 
cytokines which may take a longer time to synthesize. With the use of PD98059, an 
ERK1/2 inhibitor, PPARγ activation, COX-2 induction, an increased intracellular 15d-
PGJ2 level, and enhanced cholesterol efflux caused by SAA treatment were suppressed. 
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Secondly, our data also showed that the COX-2 overexpression stimulated by 
SAA could also through the NF-кB pathway. We showed that treatment of human HepG2 
cells with SAA resulted in the enhanced degradation of IкB and increased NF-кB 
transcriptional activity. The results from electrophoretic mobility shift assay confirmed 
that the DNA binding activity of NF-кB was increased by SAA stimulation. Our data also 
demonstrated that SAA-induced PPARγ activation was partially inhibited by the NF-кB 
pathway inhibitor, Bay 11-7082, confirming its involvement in PPARγ activation. 
Inhibition studies also showed that the same inhibitor partially suppressed the SAA-
induced COX-2 expression and 15d-PGJ2 elevation, the two essential steps in SAA-
induced PPARγ activation. Taken together, these results support that NF-кB plays an 
important role in SAA-induced COX-2-dependent PPARγ activation. Furthermore, we 
found that SAA-induced PPARγ activation was completely abolished when the ERK1/2 
and NF-кB pathways were blocked at the same time, suggesting these two pathways are 
essential in SAA-enhanced PPARγ activity. 
 
4.7 THE RECEPTORS INVOLVED IN SAA-INDUCED EFFECTS 
 The underlying mechanisms of SAA effects have raised interests on this molecule 
in recent years. Several potential receptors for SAA have been postulated, including 
scavenger receptor B-I (SR-BI) [109] and its human orthologue CLA-1 [215], receptor 
for advanced glycation end products (RAGE) [116], formyl peptide receptor-like 1 
(FPRL1) [57], hepaticexpressed Tanis receptor [122], and toll-like receptors [120]. 
Whether these receptors are essential or dispensable for SAA-induced ERK1/2 mediated 
PPARγ activation remains to be determined. 
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 The toll-like receptors (TLRs) are key players of the innate immune system, 
functioning as pattern recognition receptors that recognize a wide range of microbial 
pathogens. In addition to microbial products, several endogenous TLR ligands have been 
identified [296]. For example, high-mobility group box 1 is a ubiquitous, host-derived 
protein that interacts with multiple TLRs and plays a role in inflammation [297]. The 
presence of of endogenous TLR ligands supports the notion that TLRs play an essencial 
role in the detection of danger signals [298, 299]. The acute-phase proteins, such as SAA, 
could be danger-signaling molecules [299] which, when recognized by the host, may 
initiate immune response [298]. Seong and Matzinger have hypothesized that endogenous 
TLR ligands are characterized by the exposure of hydrophobic portions that would act as 
a universal damage-associated molecular pattern to initiate repair, remodeling, and 
immunity [299]. As SAA contains hydrophobic amino acid-rich regions that associate 
with lipoprotein and other ligands [300], it is very likely that it serves as a TLR ligand. 
SAA is also known to be a ligand for human FPRL-1 [301], which is coupled to the Gαi 
proteins for transmembrane signaling. FPRL-1 is involved in SAA-induced chemotaxis, 
proinflammatory cytokine production and secretion, and matrix metalloproteinase-9 
production [113, 115, 301]. 
 However, no data have been reported on the possible involvement of these 
receptors in SAA-induced NF-кB and PPARγ activation as well as cholesterol efflux. In 
this study, we explored the roles of FPRL-1, SR-BI, TLR2 and TLR4 in SAA stimulated 
effects. Our results provided evidence that FPRL-1, TLR2 and TLR4 may function as 
receptors for lipid-poor SAA and subsequently activate NF-кB and PPARγ. With the use 
of inhibitors for FPRL-1 (PTX) as well as SR-BI (BLT-1) and antibodies against TLR2 
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and TLR4, both NF-кB and PPARγ activity caused by SAA were significantly 
suppressed. In addition, FPRL-1 and TLR4 also play a role in SAA-induced COX-2 
expression. These results suggested that the SAA effects on NF-кB and PPARγ activation 
were regulated at least partially by FPRL-1 and TLR4. However, none of the inhibitors to 
FPRL-1, TLR2 and TLR4 could inhibit SAA-enhanced cholesterol efflux to HDL and 
apoA-I. Whether SAA-induced COX-2 expression, NF-кB and PPARγ activation is 
mediated by Tanis or RAGE remains to be determined.  
The scavenger receptor SR-BI is an HDL receptor that mediates the cellular 
uptake of cholesterol ester from HDL by selective lipid uptake [107, 108]. SR-BI-
dependent selective lipid uptake in the liver plays an important role in HDL cholesterol 
clearance, thereby facilitating reverse cholesterol transport from the periphery to the 
liver. The receptor exhibits a broad ligand binging specificity and binds low density 
lipoprotein, very low density lipoprotein, and oxidized lipoproteins in addition to HDL 
[108]. SR-BI also associates with anionic phospholipids as well as the apolipoproteins A-
I, A-II, C-III, and E, either as lipid-bound or as free apolipoproteins. In addition to 
mediating selective lipid uptake, SR-BI facilitates the efflux of cellular free cholesterol to 
HDL. Previous study had demonstrated that both lipid-free and lipid-bound SAA was 
bound and internalized by SR-BI and the SAA exerted its effect through the binding 
[109]. We examined the involvement of SR-BI in SAA-induced effects. Our data suggest 
that SAA promotes cellular cholesterol efflux through both SR-BI dependent and SR-BI 
independent pathway. However, unlike FPRL-1 and TLRs, SAA-induced COX-2 
expression, NF-кB and PPARγ activation were not affected by SR-BI inhibitor, BLT-1, 
indicating different functions of each receptor. 
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For the ligand selectivity of FPRL-1-mediated NF-кB and PPARγ activation, we 
found that only SAA and not other FPRL-1 ligands examined (MMK-1, WKYMVM, 
HFYLPM and F-peptide) could activate these effects. A previous study had shown that 
SAA did not inhibit 125I-labeled WKYMVm from binding FPRL-1 [115], suggesting that 
SAA and WKYMVm bind to FPRL-1 at different sites. Other studies also demonstrated 
that FPRL-1 could be differentially activated by distinct ligands in a ligand-specific 
manner [302, 303]. Thus, it is possible that SAA and other FPRL-1 ligands differentially 
stimulate FPRL-1 at different binding sites and subsequently induce different effects. 
 
4.8 THE ESSENTIAL ROLE OF N-TERMINAL SAA IN PROTEIN 
EXPRESSION, SECRETION, CHOLESTEROL EFFLUX AND PPARγ 
ACTIVATION 
 Most of the amyloid A peptides of the fibrils identified so far have variable C-
termini but all retain the N-terminal region [67], this region was found to contribute to the 
amyloidogenic properties of the protein [31]. Using one-dimensional Fourier analysis of 
the amino acid sequence of human SAA1 together with sequence matching to known 
secondary structural motifs, Turnell et al. predicted an extremely hydrophobic lipid-
binding N-terminus consisting of 11 amino acids residues (RSFFSFLGEAF), two helices 
and a putative calcium-binding motif [29]. The sequence between Ser-2 and Gly-8 forms 
two turns of a hydrophobic but weakly amphipathic helix. Previous data supported that 
this region played an important role in the lipid-binding property of SAA [31, 304]. In 
this study, the protein secretion and cholesterol-efflux properties of the 11 amino acids 
and the 8th residue at the N-terminal of SAA were investigated.  
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 The data showed that the total yield of wild-type SAA was much higher than 
mutant SAA proteins. While the wild-type SAA expression was around 1400 ng/ml, the 
total yield of mutant SAA was between 100-650 ng/ml. Only 32-47% of the total yield of 
mutant SAA protein was secreted to the medium compared to 90% of wild-type SAA was 
secreted. The decrease in the total yield of mutant SAA proteins and lower percentage of 
the secreted SAA protein could be explained by a lower affinity for HDL in the serum. 
Previous study had shown that free SAA was degraded faster than SAA bound to HDL, 
as the half-live of SAA was markedly reduced to a few hours when fetal calf serum 
(FCS) was omitted from the culture medium, therefore HDL protects SAA from 
degradation [31]. Because the N-terminal mutant proteins have an impaired ability to 
bind to HDL, a higher rate of proteolytic degradation is likely. This might explain the 
lower levels of the mutant SAA protein in the culture medium shown by the ELISA. The 
deletion of 11 N-terminal residues or the substitution from non-polar to polar residue at 
the 8th amino acid in SAA, changing the charge and disrupting the tertiary structure of 
SAA, result in the signigicant decrease in the lipid-binding property of mutant SAA 
proteins. Other explanations could be that the mutant mRNAs are less stable, or 
translation and secretion of mutant proteins are less efficient, because mutant mRNA 
levels are the same as in the wild-type but the cytosolic concentration of mutant proteins 
are lower than that of wild-type SAA. 
 Previously, an 18 amino-acid signal peptide that is cleaved during SAA 
maturation was identified from sequencing SAA cDNA. As the amino acid sequence of 
this peptide is similar to the sequence of signal peptides found in other human secreted 
proteins, it is proposed to be required for SAA secretion [305]. The data obtained 
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supported this hypothesis because much less of mutSAA (NLS) could be detected in 
medium as compared to the wild-type SAA when the signal peptide was deleted (Table 
5).  However, the SAA secretion was not completely inhibited which implied that SAA 
could be secreted out of the cell by a pathway independent of the signal peptide. 
 The cholesterol efflux assay results demonstrated that endogenously expressed 
wild-type SAA increased the cholesterol efflux ~ 2 folds while the cholesterol efflux 
level remained at the basal level in cells expressing mutant SAA proteins (Fig. 27), which 
indicated the essential role of the N-terminal of SAA in promoting cholesterol efflux. 
There are severl explanations for that: 1) SAA was shown to be able to exert a synergistic 
effect with HDL in promoting cholesterol efflux [110]. The total yield and secretion 
percentage of wild-type SAA was much higher than mutant SAA, therefore, the 
cholesterol efflux activity was impaired in cells expressing mutant SAA proteins; 2) SAA 
was shown to be a cholesterol efflux acceptor. The N-terminal of SAA was suggested to 
be a lipid-binding domain. 11 N-terminal deletion or substitution from Glycine to 
Aspartic acid at the 8th residue may induce a conformational change of SAA and 
subsequently impair its lipid binding ability. Under this condition, the mutant SAA could 
not function as cholesterol efflux acceptor anymore; 3) In the results section, I have 
shown that SAA could indirectly induce cholesterol efflux through PPARγ. The lower 
production of mutant SAA proteins makes this pathway impossible. Further experiments 
may be needed to prove these explanations. 
 The role of SAA N-terminal in PPARγ activation was also evaluated with this 
system. The data showed that endogenously expressed wild-type SAA could activate 
PPARγ, which is consistent with the recombinant SAA protein. The data that cells 
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expressing mutant SAA proteins could no longer activate PPARγ indicated that the 
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5.1  MAIN FINDINGS 
 In summary, this study has investigated the effects of SAA on PPARγ activation 
and the downstream cascades. The functional domain of SAA was also examined. Here 
are some of the main findings of this study. 
· SAA was found to activate PPARγ, induce ABCA1 and ABCG1 expression, and 
enhance cholesterol efflux.  
· The SAA effects were mediated through ERK1/2 and NF-кB dependent COX-2 
expression, which could increase the intracellular 15d-PGJ2, the natural ligand of 
PPARγ.  
· The receptors involved in this process include FPRL-1, TLR2 and TLR4.  
· We also established that the N-terminal of SAA was indispensable in SAA protein 
expression, secretion, cholesterol efflux and PPARγ activation. It remains to be 
determined whether the hydrophobic regions are critical for TLRs signaling by 
SAA. 
 
5.2  SUMMARY OF MAJOR CONTRIBUTIONS OF THIS STUDY 
· This study established a relationship between SAA and PPARγ, which had not 
been shown previously. The macrophages signals induced by SAA may be part of 
the protective mechanisms to prevent progression of atherosclerosis. 
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5.3  SUGGESTIONS FOR FUTURE WORK 
 This study revealed evidence that SAA-induced PPARγ activation was mediated 
by ERK1/2 and NF-кB-dependent COX-2 expression. Thus, several pathways that lead to 
the overexpression of COX-2 may also induce the activation of PPARγ. It has been 
reported that CCAAT/enhancer-binding protein-β (C/EBPβ) and AP-1 are involved in 
transcriptional regulation of the COX-2 gene [306], and MAPK signaling pathways could 
regulate C/EBPβ and AP-1 activity [307, 308]. Therefore, SAA-induced ERK1/2 
activation may regulate the activity of C/EBPβ and/or AP-1, thereby resulting in 
transcriptional activation of COX-2 gene. Further studies are needed to clarify the 
mechanisms by which SAA induces COX-2 expression. 
 SAA was shown to induce sustained ERK1/2 phosphorylation for up to 6 hours 
and the he phosphorylation level could be significantly reduced with the treatment of 
CHX, a protein biosynthesis inhibitor. CHX was also demonstrated to inhibit SAA-
induced PPARγ activation. These data suggested that other signaling molecule(s) might 
also contribute to the SAA-induced sustained ERK1/2 phosphorylation and PPARγ 
activation. It would be important to determine the molecule(s) involved in these process. 
 This project provided clear evidences that SAA could lead to PPARγ activation 
and induce cholesterol efflux in hepatocytes. However, because of the limitation of in 
vitro study, further investigations would be needed. Cultured cells in culture media are 
known to behave differently from intact cells and their interactions with the blood 
circulation, and in a larger context,  the human body . As such, in vivo study of the effects 
of SAA on atherosclerosis will be useful. An assessment of the modulation of PPARγ 
activation in animal models of atherosclerosis is now warranted to elucidate the 
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physiological relevance of SAA-induced PPARγ activation in the progression of 
atherosclerosis. SAA transgenic mice, which overexpress SAA may be a useful candidate 
to investigate the in vivo atherogenesis of sustained SAA stimulation. Additionally, 
recombinant SAA should be injected into animals to determine its effect on PPARγ.  It is 
therefore now necessary to move from an in vitro to an in vivo approach to assess the role 
of SAA-induced PPARγ activation in atherosclerosis. Only after a successful in vivo 
study with results consistent with the in vitro investigation can SAA be clearly shown to 
be involved in atherosclerosis through PPARγ. Furthermore, peptides derived from SAA, 
which could induce the antiatherosclerotic effect while avoiding the atherogenic 
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